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Abstract 
The costs associated with diagnosis, treatment and care of Alzheimer’s disease (AD) patients 
places a significant financial and social strain on healthcare systems, patients and caregivers, 
especially in low-and middle-income countries (LAMICs). Traditional methods for 
diagnosing AD are time consuming and expensive, and treatments are often only effective in 
the early stages. These factors call for the development of alternative diagnostic methods. 
One such method that has gained attention due to its neural overlaps with AD is the 
measurement of intraindividual variability (IIV; the within-person variation in performance 
over multiple trials of a single task). IIV researchers have highlighted the role of white matter 
in increased IIV, and micro-structural white matter changes have been implicated in the early 
stages of AD. The current study examined the relationship between IIV on simple and choice 
reaction time tasks and micro-structural white matter changes, as indexed by fractional 
anisotropy (FA), mean diffusivity (MD), axial diffusivity (DA) and radial diffusivity (DR) in 
a sample of 16 AD patients and 20 healthy older adults. Across the entire sample, increased 
IIV on both the simple and choice reaction time tasks was significantly correlated with lower 
FA in an area of the right hemisphere inferior longitudinal fasciculus (R-ILF). Increased IIV 
on the choice reaction time task was significantly correlated with lower DA in the same area. 
Finally, IIV on the choice reaction time task contributed significantly and uniquely to 
variance in DA in the same area. These results suggest that further longitudinal studies into 
the diagnostic utility of IIV for neurological disorders might be of value for clinicians, 
patients and caregivers.   
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Introduction 
The 20th and 21st centuries have seen a worldwide increase in life expectancy and, 
concomitantly, an increasing incidence of age-related brain disorders, including dementia. 
Global estimates suggest that, in 2016, approximately 47 million people were living with 
dementia. This number is projected to increase to 131 million by 2050. According to the 2016 
World Alzheimer’s report, the annual global cost of dementia, including costs to government, 
primary caregivers and patients themselves, is US$818 billion (Prince, Martin, Comas-
Herrera, Knapp, Guerchet, & Karagiannidou, 2016).  
Of particular concern for families, clinicians, and policymakers in low- and middle-
income countries (LAMICs) are estimates suggesting that dementia prevalence in these 
regions is in fact higher, and increasing at a faster pace, than average global rates (De Jager, 
Joska, Hoffman, Borochowitz, & Combrinck, 2015; Prince et al., 2015). Consistent with 
these suggestions are estimates that, by 2050, approximately 71% of people living with 
dementia will be resident in developing-economy countries (Prince et al., 2013). These 
countries can least afford the costs associated with the disease, which include referral to a 
specialist, initial diagnosis and treatment, continued care, and, eventually, palliative care 
(Prince et al., 2016). In addition, the social and financial burden on caregivers for those with 
dementia is often greater in LAMICs, and lower income has been associated with increased 
caregiver burden among families (Andren & Elmstahl, 2007; De Jager et al., 2015; Thrush & 
Hyder, 2014). For example, one community-based study found that that 79% of patients 
attending a South African memory clinic were cared for by family members who received 
little to no formal support, and who, in at least some cases, had to leave their jobs to fulfil this 
role (Kalula et al., 2010). 
Alzheimer’s disease (AD) is the most common cause of dementia (Anstey, Cherbuin, 
& Herath, 2013). Importantly, some treatments for AD are only effective at the early stages 
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of the disease (Kälin et al., 2014). Hence, early detection of AD is an important area of 
research and clinical interest, and investigators across the neuroscientific disciplines have, 
over the past several years, focused intensive efforts on finding methods for detecting 
cognitive and functional changes that might signal prodromal AD (Snyder et al., 2014). One 
method of measurement that is increasingly applied in AD research, in part because it might 
contribute significantly to early detection of the neurodegenerative condition, is 
intraindividual variability (IIV). IIV may be a particularly useful tool for the early detection 
of risk for AD in LAMICs because it does not involve costly neuroimaging or comprehensive 
neuropsychological test battery administration. 
IIV refers to within-person trial-to-trial variation in performance on a single task 
(Fiske & Rice, 1955a). Conventionally, studies investigating inter-individual differences in 
cognition assume that an individual’s performance is stable over time, and that any variability 
that is not accounted for by practice effects and other such factors is best regarded as noise in 
the data. An increasingly persuasive counterargument, however, is that the amount by which 
an individual’s performance varies is a function of lawful influences on behaviour, and is 
therefore relatively stable across time and across cognitive domains (Hultsch, MacDonald, 
Hunter, Levy-Bencheton, & Strauss, 2000; MacDonald, Nyberg, & Bäckman, 2006; Ram, 
Conroy, Pincus, Hyde, & Molloy, 2012; Stamps, Briffa, & Biro, 2012). 
 Individual performance that varies over macro-timescales of months, years, and 
decades reflects developmental change, and is closely linked to the aging process. In contrast, 
individual variation in performance over micro-timescales of seconds, days, or weeks is 
unrelated to developmental change, and reflects dynamic within-person characteristics (Ram 
et al., 2012). Hence, it is the latter that is of interest to IIV researchers in psychology and the 
neurosciences, and that is the focus of this thesis. 
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IIV over micro-timescales is comprised of two separate components: time-structured 
and net IIV. Time-structured IIV refers to within-person variation that is somehow related to 
time-on-task-effects, such as fatigue and practice. It is therefore measured by examining 
patterns of change within a set of repeated measurements. Conversely, net IIV refers to 
within-person variation that is unrelated to time-on-task-effects. It is measured by statistics of 
central tendency and dispersion within a set of repeated measurements (Fiske & Rice, 1955). 
Net IIV (referred to as IIV from here onwards, as it is the type of micro-timescale IIV with 
which this thesis is primarily concerned) is therefore considered a relatively stable, trait-like 
quality, and a component of cognition that exerts a non-random influence on test scores 
(Hultsch et al., 2000; MacDonald et al., 2006). 
Although IIV is stable within life stages, it increases as people move into older 
adulthood, and is negatively associated with cognitive performance in healthy adults 
(Christensen et al., 2005; Hultsch et al., 2000; Nesselroade & Salthouse, 2004). Furthermore, 
longitudinal studies of healthy older adults suggest that high IIV earlier in life can predict 
later cognitive decline. For instance, Lövdén, Li, Shing, and Lindenberger (2007) reported 
that higher IIV at baseline predicted cognitive decline in perceptual speed and ideational 
fluency up to 13 years later. Similarly, Bielak, Hultsch, Strauss, MacDonald, and Hunter 
(2010) reported that higher IIV at baseline was associated with a greater risk of non-
dementia-related cognitive impairment 5 years later. 
Furthermore, IIV can reliably distinguish between normal and pathological decline, 
and higher IIV has been associated with the clinical presence of AD compared to relatively 
lower IIV in healthy control groups (see, e.g., Gorus, De Raedt, Lambert, Lemper, & Mets, 
2008; Hultsch et al., 2000). For instance, Kälin et al. (2014) showed that individuals with 
13 
 
mild cognitive impairment (MCI)
1
 who later progressed to AD had higher IIV at baseline 
than those who did not progress. Similarly, Duchek et al. (2009) reported that IIV on two 
selective attention tasks was higher in apolipoprotein 4 (ApoE4) carriers, who are at a 
greater risk for AD, than in non-carriers, and was also positively correlated with 
cerebrospinal fluid biomarkers of AD. Recently, Christ, Thomas, and Combrinck (2018) 
found significantly higher IIV, on both time- and accuracy-based tasks, in South African 
older adults with mild-to-moderate AD than in matched healthy controls. These findings offer 
support for IIV as a sensitive marker of impending and long-term neurological change, and 
highlight the utility of using it as an early detector of AD. 
Cognitive and Neural Correlates of Intraindividual Variability 
A strong strand of research suggests that high IIV in performance on certain cognitive 
tasks is caused by lapses in executive control (Bellgrove, Hester, & Garavan, 2004; Braver, 
2012; Stuss, Murphy, Binns, & Alexander, 2003; Unsworth, Redick, Lakey, & Young, 2010; 
Unsworth, 2015). Executive control recruits regions of the prefrontal cortex (PFC), as well as 
a wider network of brain regions, and is partially responsible for a variety of performance 
outcomes. For instance, executive control underlies performance on domain-specific 
executive functioning tasks (e.g., go/no-go tasks that test response inhibition) by maintaining 
goal-relevant information in either an anticipatory or reactive manner (Braver, 2012; 
Niendam et al., 2012; Unsworth et al., 2010).  
Poor performance on tasks tapping into executive control has been related to poor 
attentional control (Kane & Engle, 2003; Unsworth et al., 2010). One paradigm used to study 
relations between executive and attentional control examines the association between 
                                                             
1 Mild cognitive impairment represents a preclinical state of cognitive decline in older adults, and 
although not always indicative of imminent dementia, is often present in the prodromal stage of Alzheimer’s 
disease. 
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performance on tasks tapping into executive control and the ex-Gaussian distribution 
parameters of reaction time (RT) tasks. RTs clustered toward the slower tail of the ex-
Gaussian distribution tend to be more variable, reflecting fluctuations in attention, whereas 
RTs clustered toward the faster tail show less variability, and thus reflect better attentional 
control (De Jong, Berendsen, & Cools, 1999). One study using this paradigm used latent 
variable analysis to test whether performance on tasks requiring a high degree of executive 
control would relate to the distribution of slower RTs, faster RTs, or both. They found that 
performance on the executive control tasks were related to the distribution of slower RTs. 
Moreover, they found that performance on fluency tasks, requiring little executive control, 
was not related to either of the RT distributions (Unsworth et al., 2010).  
In one study providing empirical support for the proposed link between IIV and 
executive control, West and colleagues (2002) found age-related increases in IIV on a task 
that required participants to press a button corresponding to a target digit (1, 2, 3, or 4), while 
ignoring a distractor letter (A, B, C, or D). In contrast, they found no age-related increase in 
IIV on a similar task that required minimal executive control (i.e., one in which no distractor 
letter was present). Similarly, Bellgrove et al. (2004) reported that IIV was a strong predictor 
of positive achievement in a sample of healthy young adults (18-36 years) performing a 
simple response inhibition task, and MacDonald, Hultsch, and Dixon (2003) found, in a 
sample of healthy older adults (54-89 years), that higher IIV was associated with poorer 
performance on an executive control task requiring retrieval of previously-learned 
information. Yet another study examined how IIV in performance on attentional control tasks 
was related to IIV in performance on a number of other domain-specific tasks in a sample of 
healthy young adults (18-35 years; Unsworth, 2015). The researchers reported that IIV on the 
attentional control tasks was related to IIV on working memory, fluid intelligence, and long-
term memory tasks. Moreover, they found that IIV on the attentional control tasks was also 
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related to everyday attentional failures, and that these failures were linked to the participant’s 
tendency to get distracted by internal thoughts, rather than by task-unrelated external stimuli. 
Taken together, these studies suggest that higher IIV might be reflective of an inability to 
maintain goal-directed information and focus, resulting in an increase in task-unrelated 
thoughts and associated lapses in attentional control.   
Neuroimaging studies provide further evidence that lapses in executive control, and 
hence in task-related attentional processes, may be associated with higher IIV in cognitive 
performance (Kelly, Uddin, Biswal, Castellanos, & Milham, 2008; Weissman, Roberts, 
Visscher, & Woldorff, 2006). Specifically, resting-state functional magnetic resonance 
imaging (fMRI) studies suggest that higher IIV may be associated with disconnections 
between the default mode network (DMN) and the task-related attentional network. The 
DMN is an interacting system of medial PFC, posterior cingulate, anterior temporal, and 
lateral parietal regions that are active in a highly correlated fashion, and in a distinct manner 
from other regions, when the scanned person is at rest. The task-related attentional network is 
a similar interacting system of PFC (dorsal, ventrolateral, and dorsomedial) and insular 
regions that are active (again in a highly correlated fashion, and in a distinct manner from 
other regions) during task performance. Kelly et al. (2008) argue that these two networks 
behave in a competitive manner. They based this argument on evidence from their fMRI 
study, which suggested that activity in the two was negatively correlated, with activation in 
one inhibiting activation in the other. Specifically, their participants performed a response 
inhibition task while being scanned, and data analyses indicated that smaller IIV on the task 
was associated with a strong negative correlation between activity in the two networks, 
whereas higher IIV was associated with a weak negative correlation.  
A separate strand of neuroimaging research suggests that impaired functioning in 
frontal, prefrontal, and parietal regions underlying performance on focused attention, 
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sustained attention, and attentional control tasks is implicated in higher IIV on those tasks 
(Bunce et al., 2007; Jackson, Balota, Duchek, & Head, 2012; Stuss et al., 2003). One finding 
that has been consistent across a number of studies, sampling from a variety of populations 
and using a variety of imaging methods, is the association between measures of IIV and 
posterior cingulate functioning. Specifically, higher IIV has been associated with increased 
micro-structural white matter changes in the posterior cingulate and decreased posterior 
cingulate activation in samples of healthy younger and older adults (Grydeland, Walhovd, 
Tamnes, Westlye, & Fjell, 2013; Jackson et al., 2012; Yarkoni, Barch, Gray, Conturo, & 
Braver, 2009), as well as with decreased posterior cingulate volume in those diagnosed with 
early AD  (Jackson et al., 2012). Importantly, the posterior cingulate has high structural and 
functional connectivity with networks involved in both internally and externally directed 
attention, and appears to play a pivotal role in executive control (Garrison et al., 2013; Leech 
& Sharp, 2013; Wen, Liu, Yao, & Ding, 2013). 
Other studies have reported significant associations between frontal and parietal 
activity and higher IIV (MacDonald, Li, & Bäckman, 2009). For instance, two fMRI studies, 
both using samples of healthy male participants, found that higher IIV on an executive 
control task was associated with (a) decreased activation in the left pregenual anterior 
cingulate (Johnson et al., 2015), and (b) increased activation in right inferior parietal and 
thalamic regions, as well as in the right inferior frontal and bilateral middle frontal regions 
(Bellgrove et al., 2004). Similarly, studies using clinical samples with frontal lesions (Stuss et 
al., 2003) and frontal lobe dementia (Murtha, Cismaru, Waechter, & Chertkow, 2002) have 
found higher IIV on executive control and RT tasks in these individuals than in those with 
non-frontal lesions and AD, respectively. 
A smaller set of neuroimaging studies, of wider scope, reports no significant 
associations between IIV and grey matter activity, but significant associations between IIV 
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and frontal, temporal, and parietal white matter tract volume, as well as inter- and intra-
hemispheric corticocortical micro-structural white matter integrity (Moy et al., 2011; Ullen, 
Forsman, Blom, Karabanov, & Madison, 2008). Those studies, then, highlight the importance 
of studying white matter changes when attempting to understand the neural bases of higher 
IIV. 
Indeed, there is now consistent and convincing evidence that disruptions in white 
matter integrity are related to higher IIV (Anstey et al., 2007; Bunce et al., 2007; Jackson et 
al., 2012; Moy et al., 2011; Stuss et al., 2003; Ullen et al., 2008). However, it is still unclear 
precisely which white matter changes are related to higher IIV. Some studies have focused on 
the relationship between IIV and micro-structural white matter changes (see, e.g., Grydeland 
et al., 2013; Lin et al., 2014; Moy et al., 2011), whereas others have focused on the 
relationship between IIV and macro-structural white matter changes, such as white matter 
hyperintensities (Bunce et al., 2007), lesions (Stuss et al., 2003), and volume (Jackson et al., 
2012). Regardless of the type of white matter changes, these studies have emphasised the role 
of functional connectivity within the brain in stable task performance (Ullen et al., 2008; 
Walhovd & Fjell, 2007). 
More specifically, these studies emphasize that the breakdown in white matter 
pathways, as a result of axonal degeneration and/or myelin thinning (as seen on, for instance, 
diffusion tensor magnetic resonance imaging (DTI)), leads to greater lapses in executive and 
attentional control and thus higher IIV (for two slightly different explanations of this view, 
see Jensen, 1992 and MacDonald et al., 2006). Within this general theoretical framework, 
decreased connectivity leads to difficulties in activating multiple brain areas in a coordinated 
way, thus explaining why higher IIV is seen especially on tasks that tap into executive 
functions (Bellgrove et al., 2004; Moy et al., 2011). Because there is evidence that sustained 
attention may rely in part on the functional connectivity of the brain (see, e.g., Morecraft, 
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Geula, & Mesulam, 1993), this theory is also consistent with the idea that lapses in attentional 
control result in higher IIV. 
In further support of the proposed relationship between some index of white matter 
change and IIV, the U-shaped function of IIV across the lifespan mirrors the inverted U-
shaped function of white matter volume throughout human development. That is, decreased 
white matter volume is associated with relatively high IIV in children due to brain 
immaturity, and in older adults due to age-related neurodegeneration (MacDonald et al., 
2006). Consistent with this suggestion, Tamnes and colleagues (2012)  found that age-related 
increases in white matter integrity were associated with lower IIV on an RT task in a sample 
of healthy children (8-19 years). Taken together with the empirical findings described above, 
there is strong evidence that white matter changes may underlie increased IIV, and that 
connections between and within brain regions supporting executive and attentional control 
may play a particularly important role. 
A common clinical observation, supported by research findings, is that executive 
dysfunction, as well as impairments in focused and sustained attention, is present in early AD 
(Baudic et al., 2006; Faust & Balota, 1997; Parasuraman & Haxby, 1993; Rizzo, Anderson, 
Dawson, Myers, & Ball, 2000; Sgaramella et al., 2001). Furthermore, Rapp and Reischies 
(2005) showed that baseline performance on tasks assessing executive control and attention 
discriminated between those who went on to develop AD 4 years later and those who did not. 
The overlap between the cognitive correlates of IIV and AD, along with findings that IIV is 
relatively higher in AD, provide strong support for studying IIV in AD samples.  
White Matter Markers of Alzheimer’s Disease Pathology 
A general consensus has emerged that there are both grey and white matter 
disruptions during the preclinical stages of AD (Braak, Heiko, Tredici, Schultz, & Braak, 
2000; Douaud et al., 2013; Johnson et al., 2015; Zhang, Xu, Zhu, & Kantarci, 2014). Many 
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studies have found evidence for white matter disruptions during the prodromal stages of the 
disease (Braak & Braak, 1991; Johnson et al., 2010; Zhang et al., 2014). Douaud et al. (2013) 
found, at baseline, greater white matter damage in the body of the fornix and in the centrum 
semiovale (i.e., at the location where the superior longitudinal fasciculus and corticospinal 
tracts cross) in those who went on to develop AD 2 years later compared to those who did 
not. These findings have been replicated and extended in other studies examining both 
macro- and micro-structural white matter damage in those with aMCI who convert to AD 
within 3 years compared to healthy controls or to those with aMCI who do not convert to AD 
within 3 years. Specifically, these studies have found reduced white matter structural integrity 
in tracts connecting limbic regions, as well in limbic-temporal white matter connections, in 
those who convert compared to healthy controls (Hong et al., 2013; Lindemer et al., 2015; 
Sun et al., 2014) and to non-converters (Rémy, Vayssière, Saint-Aubert, Barbeau, & Pariente, 
2015). 
Similarly, studies examining white matter damage in those with mild-to-moderate AD 
have found significant white matter damage in numerous white matter tracts (e.g., those 
traversing limbic, parietal, and frontal regions, and those forming fronto-occipital-parietal 
and temporo-occipital connections), as well as regions of the corpus callosum and brainstem, 
compared to age-matched healthy controls (Agosta et al., 2011; Hong et al., 2013; Serra et 
al., 2010; Sun et al., 2014; Weiler et al., 2015). A recent review of the literature on 
diencephalic connections in AD, as imaged using DTI, emphasised the role of the fornix, 
which links the medial temporal lobes and diencephalon, in the AD pathological process 
(Acosta-Cabronero & Nestor, 2014). Similarly to grey matter damage, these studies suggest a 
diffuse pattern of white matter degeneration in AD, starting in limbic and deep brain regions, 
and extending into most of the major white matter tracts in the brain, with special emphasis 
on limbic connections.  
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Apart from the later degradation of cortical association fibres as a result of grey 
matter atrophy, there is evidence suggesting that the micro-structural white matter changes 
that occur early in AD do so independently of the effects of loss of grey matter and of 
vascular pathology (Agosta et al., 2011; Gold, Powell, Andersen, & Smith, 2010; Sachdev, 
Zhuang, Braidy, & Wen, 2013; Yoon et al., 2011). White matter changes similar to those 
seen in AD are present in the brains of patients with pre-clinical AD, and some of these 
changes differ from the gross white matter changes caused by vascular pathology (de la 
Monte, 1989). Numerous independent studies report that cognitively normal participants with 
high genetic risk for AD present with significant white matter changes, with no differences in 
grey matter volume, when compared to cognitively normal individuals with low genetic risk 
for AD (Gold et al., 2014; Heise, Filippini, Ebmeier, & Mackay, 2011; Molinuevo et al., 
2014; Selnes et al., 2012). 
One longitudinal study found, at baseline, significant reductions in white matter 
integrity in areas similar to those seen in AD in a cognitively normal sample who went on to 
develop aMCI 2 years later, compared to those who did not go on to develop aMCI. Of note 
here is that the analyses in that study detected no significant between-group differences in 
any grey matter structures at baseline (Zhuang et al., 2012). In a similarly-designed study, 
Rieckmann et al. (2016) examined the association between markers of AD risk at baseline 
and micro-structural white matter changes 2.6 years later in a sample of healthy older adults. 
They found that baseline measures of amyloid burden were associated with greater micro-
structural white matter changes in the parahippocampul cingulum, and that some of these 
changes were independent of changes in hippocampal volume due to amyloid burden. The 
growing body of evidence for an independent role of white matter in AD neurodegeneration 
has provided the impetus for more thorough investigations of the types of white matter 
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changes (e.g., demyelination or axonal degeneration) that may be involved in the disease 
process.  
Diffusion tensor imaging and micro-structural white matter changes. Diffusion-
weighted MRI (DWI) was first described in the mid-1980s (see, e.g., Le Bihan et al., 2001). 
The basic principle behind DWI relates to the random movement of water molecules (viz., 
the distribution of displacement). This term describes the direction and distance of the 
movement of water molecules from a central point over a specific time period. Without any 
barriers, the distribution of displacement of water molecules over time is completely random. 
However, the presence of physical barriers (e.g., such as those found in organic tissue) affects 
the distribution of displacement such that it is no longer random. Measuring the distribution 
of displacement of the water molecules in and around organic tissue therefore provides 
information on the structure of the surrounding tissue. Using a combination of traditional 
MRI techniques and bipolar magnetic field gradient pulses, DWI is able to obtain a six-
dimensional representation of the distribution of displacement within a single tissue voxel in 
the human body. This representation provides unique information about the location, density, 
and integrity of the surrounding tissue.  
DTI is a variant of DWI. Originally developed to better measure the direction of water 
displacement within a tissue voxel, it has become one of the most common methods used to 
examine micro-structural white matter changes in both clinical and healthy populations 
(Alexander, Lee, Lazar, & Field, 2007; Bammer, 2003; Winklewski et al., 2018).Using a 
series of diffusion-weighted images, DTI yields three diffusivity parameters (λ1, λ2 and λ3) 
corresponding to parallel (λ1) and perpendicular (λ2 and λ3) diffusivity. Axial diffusivity 
(DA) describes the overall displacement parallel to the axon, whereas radial diffusivity (DR) 
describes the overall displacement perpendicular to the axon. Because white matter is highly 
directional (anisotropic), one expects highly directional water diffusion along the direction of 
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the tissue fibre in healthy white matter. Hence, non-directional (isotropic) diffusion in white 
matter is indicative of a loss of structural integrity or density. 
These measurement bases allow DTI to yield two main determinants of white matter 
integrity. Fractional anisotropy (FA) describes the total degree of water diffusion along the 
tissue fibre, and is represented as a scalar value between 0 (isotropic) and 1 (anisotropic). 
Mean diffusivity (MD), on the other hand, describes the average water diffusion within a 
tissue voxel in both directions, and represents the overall displacement of molecules and 
presence of obstacles to water diffusion.  
 Relatively high FA and lower MD values are associated with healthy white matter. 
FA values in healthy human white matter are usually > 0.2, while MD values in healthy white 
matter vary depending on the tissue organisation within a particular voxel (Mori & Zhang, 
2006). Although DTI parameters should always be interpreted with caution, many studies 
suggest they can indicate different kinds of changes in tissue micro-structure (Alexander et 
al., 2007; Soares, Marques, Alves, & Sousa, 2013). Relatively low FA values have 
consistently been found in a number of pathological processes known to affect the structural 
integrity of white matter. Due to its non-specific nature, though, the specific kind of micro-
structural damage reflected by FA values has not yet been determined (Alexander et al., 
2007). On the other hand, relatively higher MD in the absence of lowered FA often indicates 
a breakdown in myelin integrity or density (Alves et al., 2012). In addition, multiple animal 
studies have found relatively high DR values in experimentally induced demyelination, with 
little to no change in DA values (Song et al., 2002; Sun et al., 2006). Conversely, animal 
studies, as well as a collection of human studies, have found relatively low DA values to be 
associated with a greater degree of axonal damage (Gold, Johnson, Powell, & Smith, 2012; 
Sun et al., 2006). For a further explanation on DTI interpretations, see Alexander et al. 
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(2007). For a brief technical review on inferring the type of tissue changes associated with 
DA and DR, see Winklewski et al. (2018). 
Micro-structural white matter changes in Alzheimer’s disease. The exact 
mechanisms of micro-structural white matter changes in AD are still being investigated. 
Sjöbeck, Haglund, and Englund (2005) suggest that myelin changes during AD progression 
result from a series of minor ischemic events that lead to a loss of oligodendrocytes and 
subsequent reductions in myelin integrity. This theory stands in contrast to the retrogenesis 
theory of white matter degeneration in AD (Reisberg et al., 1999). The latter postulates that 
late-myelinating axons with a smaller axonal circumference are more susceptible to damage 
arising from a number of sources, including brain oxidation. Hence, the proposal is that these 
late-myelinating axons are the first to be affected in the AD degenerative process. For a 
review of this theory, see Alves et al. (2015). 
Several longitudinal studies have used DTI to examine micro-structural white matter 
changes across AD progression (see Amlien & Fjell, 2014 and Sexton, Kalu, Filippini, 
Mackay, & Ebmeier, 2011 for two slightly different reviews). For example, Kitamura et al. 
(2013) reported finding significant decreases in FA and increases in DR, but no changes in 
MD or DA, over an 18-month period in a sample of participants with mild AD at baseline. 
Another longitudinal study replicated this finding, using a sample of patients diagnosed with 
very mild to mild AD (Acosta-Cabronero, Alley, Williams, Pengas, & Nestor, 2012). 
Conversely, other longitudinal studies have reported finding significant increases in MD, but 
no changes in FA, over a 12-month period in samples of participants with mild AD at 
baseline (Firbank et al., 2016; Nowrangi et al., 2013). These longitudinal studies are 
suggestive of both axonal breakdown and a loss of myelin integrity influencing longitudinal 
micro-structural white matter integrity loss in AD.  
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Regardless of the exact mechanism of white matter pathology, and whether it relates 
to loss of myelin integrity or axonal degeneration, there is evidence from animal and human 
neuropathological studies suggesting that a loss of micro-structural white matter integrity 
might be a causal factor in AD neuropathology (Desai et al., 2009; Stokin et al., 2005). One 
such study, using a mouse model of AD, found that disruptions in axonal transport tended to 
result in more axonal damage, distinct from that seen in the normal AD process, more than 1 
year before the presence of any disease-related pathology. This early axonal damage was 
linked to disruptions in axonal transport, resulting in further axonal damage and triggering an 
increase in production of amyloid-β peptides and in subsequent amyloid deposition (Stokin et 
al., 2005). Importantly, the authors found similar early axonal damage to that seen in the 
mouse model in a human sample with early AD. 
In support of the above, another animal study found evidence of myelin disruption in 
the hippocampus and entorhinal cortex of mice prior to the formation of the neurofibrillary 
tangles and amyloid-β plaques that are characteristic of AD pathology (Desai et al., 2009). 
The authors of that study suggested that the observed myelin disruption might occur as a 
result of damage to oligodendrocytes, which are known to play a role in the myelination 
process. They further speculate that this damage results in a loss of myelination, and a 
subsequent decrease in axonal transport, resulting in axonal damage and the cognitive deficits 
seen in early AD. 
Taken together, these human and animal neuropathological studies suggest that 
micro-structural white matter changes occur early in AD and might be a causal factor in the 
neuropathology characteristic of that neurodegenerative disorder. 
Distribution of micro-structural white matter integrity loss in Alzheimer’s 
disease. Despite a growing body of evidence indicating early compromise of micro-structural 
white matter integrity in AD, it is unclear exactly which brain regions might be affected 
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consistently by those changes. In an attempt to provide some clarity around these issues, 
Sexton et al. (2011) conducted a meta-analysis of studies that used region of interest (ROI) 
analyses to examine white matter changes in AD and MCI. Their analysis consisted of 41 
studies published between 1980 and February 2010, all of which compared an AD/MCI 
group to a group of matched healthy controls. They selected only studies that used manual 
tracing, masking, or tractography to examine pre-defined ROIs. Subsequent analyses 
included a total of 2026 participants: 617 AD patients, 494 MCI patients, and 915 controls. 
Their quantitative summary found that, in AD/MCI participants relative to controls, (a) FA 
was decreased in all brain regions except for internal capsule and parietal areas; (b) the 
largest effect sizes for FA were in the uncinate fasciculus, superior longitudinal fasciculus, 
and posterior sections of the cingulum; (c) medium effect sizes for FA were found in the genu 
and splenium of the corpus callosum, as well as anterior sections of the cingulum; and (d) 
MD was increased in all brain regions, with the largest effect sizes in the hippocampus as 
well as in other temporal and parietal areas.  
Subsequent studies also using ROI analyses have replicated these findings. 
Specifically, damage to micro-structural white matter of AD patients has consistently been 
found in the hippocampus, fornix, cingulum, right inferior longitudinal fasciculus, and areas 
of the corpus callosum, when compared to patients with MCI or to healthy controls (Alves et 
al., 2012; Hong et al., 2013; Lee et al., 2015; Nowrangi et al., 2013; Tang et al., 2017; Tang, 
Qin, Zhu, & Miller, 2017; Zhang et al., 2014). In one ROI study suggesting that such white 
matter changes appear preclinically, researchers found increased micro-structural white 
matter damage in the left fornix and right inferior longitudinal fasciculus (R-ILF) in a group 
of healthy adults with cerebrospinal fluid biomarkers for AD, compared to a group of healthy 
adults with no such biomarkers (Gold et al., 2014).  
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Other studies using whole-brain analytic methods, rather than ROI analyses, to study 
white matter changes in AD have replicated the patterns of data described above. 
Specifically, these studies have found, in samples with AD, aMCI or MCI, but not in healthy 
controls, evidence for micro-structural white matter damage in the hippocampus, fornix, 
cingulum, inferior longitudinal fasciculus, and areas of the corpus callosum (Kim et al., 2015; 
Wang & Wang et al., 2015). Others using the same analytic method have found additional 
micro-structural white matter damage in the superior longitudinal fasciculus, anterior 
thalamic radiations, cortico-spinal tract, and the inferior fronto-occipital fasciculus in those 
with AD relative to healthy controls (Rémy et al., 2015; Teipel et al., 2014). In one whole-
brain analysis study suggesting that white matter changes appear preclinically, researchers 
found such changes in the corona radiata, internal capsule, left fornix, superior longitudinal 
fasciculus, uncinate fasciculus, inferior fronto-occipital fasciculus and areas of the corpus 
callosum in those with preclinical AD compared to a control group with no AD biomarkers 
(Molinuevo et al., 2014). 
In summary, although it is still unclear which white matter changes occur first in the 
AD process, and where they occur, the studies reviewed above suggest strongly that white 
matter changes may serve as a pre-clinical marker of AD.  
Rationale, Aims, and Hypotheses 
Taken together, the studies reviewed above provide convincing evidence for both a 
cognitive and neural overlap between IIV and AD. This evidence, along with consistent 
evidence that IIV is relatively higher in individuals with AD, and that higher IIV is often a 
marker of pathological cognitive decline in older adults, provides sufficient reason for using 
an AD population to further study the neural mechanisms underlying IIV.  
Although the findings discussed above highlight the possible utility of studying the 
relationship between IIV and white matter changes in AD, only one published study has 
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examined this relationship. Jackson and colleagues (2012) used a conventional MRI ROI 
approach to study total cerebral white matter volume, as well as superior frontal gyrus, 
ventral and dorsolateral PFC, anterior and posterior cingulate, precuneus, and inferior parietal 
lobe volume, using the primary visual cortex as a control ROI. They found a significant 
positive correlation between loss of white matter volume in the superior frontal gyrus, 
posterior cingulate, precuneus, and ventral and dorsolateral PFC, and reaction time IIV 
(IIVRT) in a sample of early-stage AD patients and healthy controls. They found no 
significant correlations between white matter volume in the anterior cingulate, inferior 
parietal lobule, or primary visual cortex and IIVRT within either group. Furthermore, the 
correlation between total cerebral and regional white matter volume and IIVRT was not 
significantly stronger in patients than in controls, even though IIVRT was higher in patients 
than in controls. It is possible that the lack of the predicted stronger correlation between white 
matter volume and IIVRT in patients was due to the specific sample of early-stage AD patients 
these researchers used. On average, those participants had relatively high education levels 
and socio-economic status, and thus may have had high enough cognitive reserve to 
compensate for potentially impairing effects of the observed organic changes on cognition 
(Tucker & Stern, 2011). 
The current study aims to extend the findings of Jackson et al. (2012) by examining 
the relationship between IIVRT and micro-structural white matter changes, as indexed by DTI, 
in a sample of older adults with mild-to-moderate AD and a group of age-matched healthy 
controls. It tested the hypothesis that IIVRT contributes significantly and independently from 
age, sex, level of education, household income and mean RT latencies to micro-structural 
white matter changes in a group of AD patients and age-matched healthy controls. 
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Methods 
Design and Setting 
This study examined the association between white matter changes and IIVRT in 
samples of (a) patients diagnosed with possible or probable AD, in the mild-to-moderate 
stages of the disease, and (b) demographically matched healthy controls. It forms part of a 
larger longitudinal research program that tracks the progression of cognitive decline in AD 
(Christ et al., 2018), using RT outcome data from that parent study’s neuropsychological test 
battery. Furthermore, DTI data for each participant (which were used to index white matter 
changes) were obtained from an MRI scan that took place not more than 6 months after 
cognitive testing. 
The study used a measurement-burst design (Fiske & Rice, 1955). Such a design 
consists of repeated assessments on the same task over multiple time-frames. Specifically, I 
obtained from each participant a measurement of IIV for each of two administrations of two 
different RT tasks (simple and choice) on each of 3 days of testing (see Figure 1). Each 
administration of each RT task consisted of 30 trials, although significant correlations 
between frontal white matter changes and IIVRT have been found using as few as 20 trials per 
administration (Bunce et al., 2013). The six administrations of each of the RT tasks were used 
to calculate net IIV for both the simple and choice tasks, for each of the participants. 
Previous studies investigating the relationship between white matter changes and IIV 
have only measured IIV in micro-time (i.e., minutes or hours; see, e.g., Jackson et al., 2012; 
Moy et al., 2011). Although there is evidence that the time-frame across which IIV is 
measured plays an important part in the measurement outcome (Ram & Gerstorf, 2009), no 
published study has assessed white matter changes and IIV in macro-time (e.g., days, weeks). 
A measurement-burst design consisting of multiple repeated assessments on the same task 
over multiple time-frames, and calculating net as opposed to time-structured IIV, means one 
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is better able to ensure that the variance being measured is a reflection of each individual’s 
true variability, rather than a reflection of group and time-on-task effects such as learning or 
fatigue (Ram & Gerstorf, 2009).  
All cognitive testing took place in a private room in the Geriatric Unit at Groote 
Schuur Hospital (GSH) in Cape Town, or in a quiet room in the participant’s home, 
depending on what was more convenient for him/her. MRI scans were taken at the Cape 
University Body Imaging Centre (CUBIC), located at GSH. 
 
 
Figure 1. Measurement-burst design used to collect reaction time data on the simple and choice 
reaction time tasks. 
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Participants 
Eligibility criteria. These were identical to those applied in the parent study. 
Individuals were eligible for participation if they (a) had a readily available and accessible 
medical history; (b) were aged 55 years or older; (c) had basic English literacy (i.e., ability to 
speak, read, and write fluently in that language); and (d) could identify a close relative or 
informant who could provide collateral information (e.g., regarding cognitive changes in 
clinical participants). 
Individuals were excluded from participating if they reported or if their medical 
records showed: (a) uncontrolled hypertension, diabetes mellitus, or another cardiovascular 
disease; (b) a diagnosis of HIV/AIDS; (c) a current diagnosis of a psychiatric illness; (d) a 
history of stroke or other major neurological disorder; (e) a history of alcohol or drug abuse 
or heavy smoking (> 20 cigarettes per day). Individuals with a score > 9/30 on the Geriatric 
Depression Scale (GDS; Yesavage, Brooks, Taylor, & Tinklenberg, 1993) were also 
excluded from participating. These criteria were applied because of their known effects on 
cognitive performance in AD (Arvanitakis, Wilson, Bienias, Evans, & Bennett, 2004; 
Bernardin, Maheut-Bosser, & Paille, 2014; Etkin, Gyurak, & O'Hara, 2013; Gorelick et al., 
2011; Grant, Contoreggi, & London, 2000; Hagen et al., 2016; Jokinen et al., 2015; Makin, 
Turpin, Dennis, & Wardlaw, 2013; Rincon & Wright, 2013; Swan & Lessov-Schlaggar, 
2007; van den Kommer, Tessa N et al., 2013; Wang & Blazer, 2015). Participants with a 
Mini-Mental State Exam (MMSE; Folstein, Folstein, & McHugh, 1975) score of less than 12 
were also excluded. This criterion was applied to ensure that individuals with severe 
cognitive impairment would not be part of the sample. 
AD patients. Clinical participants (n = 29) who met criteria for mild-to-moderate 
stage possible or probable AD were recruited into the parent study from the GSH Memory 
Clinic, which is administered by the University of Cape Town’s Division of Geriatric 
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Medicine and the Albertina and Walter Sisulu Institute of Ageing in Africa. Patients with 
suspected age-related memory disorders are referred to the Memory Clinic from primary 
healthcare institutions in Cape Town and surrounding areas (Kalula et al., 2010). Potential 
clinical participants were approached by one of the Memory Clinic staff members, who 
provided them with information about the study (see Appendix A).  
All clinical participants met the Diagnostic and Statistical Manual – Fourth Edition 
(DSM-IV; American Psychiatric Association, 2000) criteria for AD (see Appendix B). They 
also fell within the mild-to-moderate range on the Clinical Dementia Rating (CDR) scale (see 
Appendix C). Diagnosis was finalised by the team of health professionals working at the 
Memory Clinic. That team includes individuals from the fields of geriatric medicine, 
psychiatry, neurology, and neuropsychology. 
Of the 29 clinical participants recruited into the study, data from 16 (12 women) 
formed part of the final statistical analyses. Of these 16 participants, 15 were diagnosed with 
possible or probable AD and one was diagnosed with mixed AD and vascular dementia. 
Attrition that led to the loss of data from 13 participants is accounted for as follows: 
(a) 5 individuals were ineligible to continue after the screening phase (i.e., they 
did not meet the eligibility criteria described above); 
(b)  2 individuals (a 71-year old woman and a 78-year-old woman) were lost to 
follow-up after the second wave of testing; 
(c) 2 participants (an 87-year-old woman and a 78-year-old woman) did not 
complete the scan due to feelings of claustrophobia while in the scanner; 
(d) 1 participant (a 77-year-old man) did not consent to the scanning phase of the 
study; 
(e) 2 datasets (one from a 65-year old man, and the other from a 74-year-old man) 
were removed due to a high number of missing slices; 
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(f) the dataset from a 79-year-old man was removed because the patient evinced 
extensive brain atrophy; 
Healthy controls. I recruited control participants (n = 35) from various 
establishments in Cape Town and surrounding areas. Together with the parent study’s 
principal investigator (PI), I searched for seniors’ clubs, retirement centres, and doctor’s 
offices in the areas surrounding GSH. We contacted doctor’s secretaries and chairpeople of 
the identified establishments and provided them with details of the research study. We then 
followed necessary protocols for recruiting individuals from each establishment. These 
protocols involved setting up appointments via the chairpeople of the identified 
establishments and conducting informal information sessions during which we enquired 
whether individuals would participate in the research. Alternatively, they involved 
distributing flyers (see Appendix D) to the identified establishments and following up with 
individuals who contacted us expressing an interest in participating. I also recruited some of 
the healthy relatives who accompanied the clinical participants to their testing sessions. 
Of the 35 control participants recruited into the study, data from 20 (14 women) 
formed part of the final statistical analyses. Attrition that led to the loss of data from 15 
participants is accounted for as follows: 
(a) 7 individuals were ineligible to continue after the screening phase (i.e., they did 
not meet the eligibility criteria described below);  
(b) 2 participants withdrew from the study following the screening phase; 
(c)  1 participant, a 73-year-old woman, was lost to follow-up at the second wave of 
testing; 
(d) 1 participant, a 75-year-old-woman, withdrew from the study after the second 
wave of testing; 
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(e) 2 participants were ineligible for the scanning phase of the study: an 88-year-old 
woman had had a pacemaker implanted, and a 73-year-old woman was unable to 
lie in the correct position for the duration of the scan 
(f) 2 participants (a 66-year old woman and a 76-year-old woman) did not consent to 
the scanning phase of the study. 
Figure 2 provides a complete breakdown of participant attrition throughout each 
phase of the study. 
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Figure 2. Diagram illustrating the number of participants (healthy controls and AD patients) 
enrolled in the study, as well as details relating to exclusion. 
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Measures 
Screening measures. These measures helped ensure participants met the eligibility 
criteria described above. 
Geriatric Depression Scale (GDS). This 30-item self-report instrument is a valid and 
reliable measure of depressive symptoms in the elderly (Yesavage et al., 1983). The GDS can 
accurately distinguish between those who are depressed and those who are not depressed, in 
both healthy individuals and those with dementia (Goodarzi, Mele, Roberts, & Holroyd-
Leduc, 2017; Li et al., 2015). The GDS developers report that it has demonstrated good 
convergent validity, correlating at .84 with the Self-Rating Depression Scale (Zung, 1965) 
and at .80 with the Hamilton Rating Scale for Depression (Hamilton, 1960). The developers 
also report a median correlation of .56 between the 30 items on the scale and the corrected-
item total score, an inter-item correlation of .36, and an alpha coefficient of .94 for overall 
internal consistency. Furthermore, they report good split-half reliability (r = .94) and good 
test-retest reliability (r = .85; Yesavage et al., 1983). The GDS has been used successfully in 
South African clinical practice and research studies (see, e.g., Dorsey, Rodriguez, & 
Brathwaite, 2002). 
Cambridge Examination for Mental Disorders of the Elderly - Revised (CAMCOG-
R). The CAMCOG-R, a multi-dimensional assessment of cognitive functioning, is part of the 
Cambridge Examination for Mental Disorders of the Elderly – Revised (CAMDEX-R; 
Huppert, Brayne, Gill, Paykel, & Beardsall, 1995). It is commonly used as a screening tool 
for dementia, and has demonstrated high test-retest and inter-rater reliability (O'Connor, 
Daniel W. et al., 1989). We used a version of this measure that has been adapted for use in 
South African populations, and that has been used successfully in previously published 
studies from our laboratory (Christ et al., 2018; James, Grace, Thomas, & Combrinck, 2015).  
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Mini-Mental State Examination (MMSE). This 19-item instrument (Folstein et al., 
1975), one of the most commonly used dementia screening measures, is administered as part 
of the CAMCOG-R. In the current study, it was used to measure the severity of overall 
cognitive impairment. The MMSE has good inter-rater reliability, internal consistency, and 
test-retest reliability (Baek, Kim, Park, & Kim, 2016; Boban et al., 2012; Folstein et al., 
1975; O'Connor et al., 1989). It has been used successfully in several previously published 
South African studies (Adam, Godlwana, & Maleka, 2016; Christ et al., 2018; James et al., 
2015; Ramlall, Chipps, Pillay, & Bhigjee, 2013). 
Reaction time measures. Reaction time (RT) is typically considered to be the time 
between the presentation of a stimulus and the beginning of the participant’s response to that 
stimulus. RT tasks are particularly effective measures of IIV because, given that outcomes 
can be measured precisely (e.g., in milliseconds) using computer software, they are sensitive 
to even minor performance fluctuations. RT tasks are also less sensitive than accuracy-based 
tasks to practice effects, and so can be administered multiple times within one testing session. 
These characteristics allow for the examination of IIVRT within a single testing session. 
Hence, RT tasks have been used to measure IIV in many previously published studies 
(Anstey et al., 2007; Fiske & Rice, 1955; Hultsch et al., 2000; Jackson et al., 2012; 
MacDonald et al., 2003; Moy et al., 2011; Nilsson, Thomas, O'Brien, & Gallagher, 2014).  
I computed IIVRT by measuring performance variability on the Simple Reaction Time 
(SRT) and Choice Reaction Time (CRT) subtests of the Cambridge Neuropsychological Test 
Automated Battery (CANTAB; Fray, Robbins, & Sahakian, 1996).  These subtests were 
administered on a Windows 8.1 touchscreen device, with a 10.1” screen size, and carrying the 
CANTAB-minimum specifications (1 GHz processor, with 2 GB RAM and 1 GB free disc 
space). Two USB ports, as well as sound and display adapters compatible with Microsoft 
DirectX 9.0 or later, built-in speakers, and a press pad were also used. 
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The CANTAB is a widely published computerised neuropsychological test battery 
and has been reviewed extensively (Égerházi, Berecz, Bartók, & Degrell, 2007; Lowe & 
Rabbitt, 1998; Wild, Howieson, Webbe, Seelye, & Kaye, 2008; Zygouris & Tsolaki, 2015). 
Furthermore, the CANTAB SRT and CRT tasks have high test-retest reliabilities, with 
intraclass coefficients of .80 and .79, respectively (Lemay, Bédard, Rouleau, & Tremblay, 
2004; Lowe & Rabbitt, 1998). 
The SRT task requires participants to monitor, while holding down a press pad with 
the index finger of the dominant hand, the centre of a computer screen for the appearance of a 
yellow dot inside a white circle. When the dot appears, they must release the press pad and 
touch inside the white circle on the screen, with the index finger of the dominant hand, as 
quickly as possible. The stimulus was present on the screen for 250ms and participants had 5s 
to respond to the stimulus before the next trial started, with an inter-stimulus delay of 
between 750 and 2250ms. The CRT task works similarly in that the participants monitor the 
centre of a computer screen for the appearance of a yellow dot inside a white circle, except 
the yellow dot can appear in any one of five white circles and they are required to select 
between these five circles when signalling the appearance of the yellow dot. Figure 3 
provides a visual depiction of the tasks.  
Participants were allowed to practice each of these tasks for 10 trials before testing 
began. They were permitted to move on to the testing phase after achieving 90% accuracy for 
the first practice phase or, failing that, after completing a second practice phase. The test 
phase for both RT tasks consisted of 30 trials, and took approximately 5 minutes per 
administration. 
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Figure 3A. Simple reaction time task of the Cambridge Neuropsychological Test Automated Battery. 
Participants must release the press pad and touch inside the white circle as soon as the yellow dot appears.  
Figure 3B. Choice reaction time task of the Cambridge Neuropsychological Test Automated Battery. 
Participants must release the press pad and touch inside the upper-most white circle as soon as the yellow 
dot appears. 
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Diffusion tensor imaging acquisition. Each participant was imaged on a 3-Tesla 
Siemens Skyra MRI machine. Appendix E describes the parent study’s MRI scanning 
protocol (total time = 45 min) from which the current DTI data were acquired. Two DTI 
acquisitions with alternating phase encoding directions (i.e., anterior–posterior and posterior–
anterior (AP-PA)) and a T1-weighted high-resolution structural image were required to 
produce data relevant to the current study’s aims. 
Procedure 
After an individual had given verbal consent for participation, either the parent 
study’s PI, myself, or another graduate student scheduled the screening session. 
Screening phase. After participants had signed the consent form (see Appendix F) 
and indicated they understood its contents, the PI of the parent study, myself, or another 
graduate student administered the screening tests. This administration occurred in a private 
examination room in the Geriatric Unit at GSH, or in a quiet room in the participant’s home. 
Participants were assessed individually (although, in the case of clinical participants, a 
relative or friend remained present in the room). The test administrator calculated scores on 
each of the screening measures. These scores were then checked against the eligibility criteria 
by the PI of the parent study. 
Individuals who did not meet the eligibility criteria described above were dismissed 
from the study after being given an appropriate explanation and debriefing. Those who were 
excluded from participation due to their GDS scores were given a note stating their score that 
they could give to their primary care physician. Those who were excluded from participation 
due to a DSM-IV diagnosis of major neurocognitive impairment were referred to the GSH 
Memory Clinic if they were not already patients there. 
Individuals who met the eligibility criteria were scheduled for their first test session 
by the PI of the parent study, myself, or another graduate student. 
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Test phase. This phase was initiated within 30 days of screening. Individual face-to-
face testing took place in a private room in the Geriatric Unit at GHS, or in the participant’s 
home, depending on what was most convenient for him/her. For the clinical participants, a 
relative or friend remained present in the room for the testing session. The decision to allow a 
familiar person in the room during testing was made to avoid any unnecessary distress that 
could potentially impact on performance. 
I collected IIVRT data from three testing sessions. These sessions took place within a 
2-week span, with seven days separating each test session (see Figure 4). During each of the 
three sessions, each participant completed two SRT and two CRT tasks. Each of these six 
tasks consisted of a 30-trial block (see Figure 1). Each session therefore comprised 60 trials. 
The order in which participants completed the RT tasks relative to the other tests they 
completed as part of the parent study was counter-balanced so as to avoid order effects. 
Participants always completed the SRT task before completing the CRT task, however.  
Neuroimaging phase. All scans were conducted by a CUBIC MRI technician. 
Participants were asked during one of the three test sessions, or telephonically following the 
third such session, if they would agree to participate in this phase of the study. Those who 
verbally consented to undergo an MRI scan were asked to complete an MRI compatibility 
check-list either during the same telephone conversation or in person at the time of the scan 
(see Appendix G). Participants who were MRI compatible were booked for a scan on a date 
not more than 6 months after their third test session. 
Upon arrival at the scanning centre, each participant was required to sign an MRI-
specific consent form (see Appendix H) and to complete and sign a new MRI compatibility 
check-list. I explained each section of the consent form to them, and either I or an MRI 
technician answered any questions they had.  
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After signing the consent form, participants were taken into the scanning room and 
briefed on the coming procedure by an MRI technician. They were instructed that once inside 
the scanner they would need to keep their heads still. They were informed that the scanner 
would make a series of loud noises, and that during one of the sequences the bed would 
vibrate slightly. They were provided with a panic button and told that they should push it if 
they wanted the scan to stop immediately. Before lying down on the bed, participants were 
provided with noise-cancelling earplugs. Once participants were lying down, the MRI 
technician placed foam padding around their heads within the head coil. This helped reduce 
head movement during the scan. The bed then moved into the scanner. Once the door of the 
scanning room was closed, participants were informed that the scan was about to begin. 
 
 
Figure 4. Timeline of the screening, test, and neuroimaging phase of the study. 
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Data Management and Statistical Analyses 
Filtering SRT and CRT data. I examined data from the SRT and CRT tasks for 
outliers in order to remove from the final dataset responses that were either very slow or very 
fast. Very slow responses may have been the result of participants getting distracted, whereas 
very fast responses may have been the result of participants releasing the button accidentally 
or in premature anticipation of stimulus appearance. The upper limit for response times in 
each block was set at 3 SDs above the mean for that block, calculated separately for clinical 
and control groups. This limit is consistent with that set by other studies examining IIVRT 
(see, e.g., Bielak et al., 2010; Hultsch et al., 2000). The lower limit for response times was set 
at 150 milliseconds. The decision around this criterion is based on evidence that it takes the 
average adult approximately 150 milliseconds to examine visual stimuli and decide on a 
response (Thorpe, Fize, & Marlot, 1996). Any responses occurring sooner than this cut-off 
were therefore excluded on the assumption that they did not involve any decision-making 
processes. There were 278 values that needed to replaced, accounting for 1.96% of the RT 
dataset. 
Values identified as outliers and missing values due to invalid responses were 
replaced using a multiple imputation technique. In SPSS (version 25.0), I selected the 
“Mersenne Twister” random number generator and fixed the starting point at 2 000 000. I 
then imputed the missing/outlier data points for each administration of both the SRT and 
CRT tasks for all participants. For each administration of each task, only the trials from that 
specific administration were used as predictors. I set SPSS to run five imputations, and 
manually calculated the average value across these five imputations for each of the 
missing/outlier data points. The average imputed value for each data point was then used to 
replace the missing value (Enders, 2017). This method was used instead of replacing 
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missing/outlier values with the mean value for each administration, as the latter method 
unavoidably reduces variability in the dataset. 
Extracting intraindividual variability data. Net IIV differs theoretically from time-
structured IIV in that it is believed to reflect a measure of variability that is independent of 
group and time-on-task effects (Ram & Gerstorf, 2009). To partial out these effects, two 
mixed-effects models were run using SPSS (version 25.0), with either SRT or CRT latency as 
the outcome variable. The participant’s ID was entered as the subject variable in both models. 
The main effects of group status, age, sex, household income, and years of education were 
entered as one block to determine the influence of group effects on RT latency. The main 
effects of test order (one to three), trials (1-30), administrations (one to six), and interval (one 
to three) were entered as a single block to determine the influence of time-on-task effects on 
RT latency.  
Calculating the intraindividual standard deviation (iSD). I determined net IIV by 
calculating the intraindividual standard deviation (iSD) over the 180 trials of both the SRT 
and CRT tasks for each of the participants. Measures of iSD are used by many IIV 
researchers as indices of stability, and are among the most commonly used methods for 
calculating net IIV (Bielak et al., 2010; Gorus et al., 2008; Grydeland et al., 2013; Hultsch et 
al., 2000; Moy et al., 2011; Ram & Gerstorf, 2009; Stuss et al., 2003; Tamnes et al., 2012; 
Walhovd & Fjell, 2007).  
To obtain the iSD over all 180 trials, I first calculated the SDs for each of the six 
administrations of the SRT and CRT tasks. I then calculated the average SD for each day of 
testing. I did this by finding the mean of the SDs for both administrations of each task during 
test sessions one, two and three. As a final step, I calculated the average SD across the 3 days 
of testing by finding the mean of the SDs for test sessions one, two, and three for both RT 
tasks. This gave me an overall iSD score for each participant, for each task (see Figure 5). I 
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chose this method because it made the most theoretical sense when considering the nature of 
IIV, and how the data were structured in time.  
DTI pre-processing. The DICOM images were converted to NiFTi format using the 
dcm2nii command in AFNI. All DTI data were first inspected visually for the presence of 
dropout slices and motion artifacts, which were removed from both AP and PA acquisitions. 
Pre-processing included motion, eddy current, and susceptibility (Andersson, Skare, & 
Ashburner, 2003) corrections using TORTOISE V.2.5.2 (Pierpaoli et al., 2010). Each 
subject’s T1 image was converted to a T2-weight contrast image using the relative contrast of 
tissues methods (Taylor et al., 2015), which had a B0 contrast for the default setting in 
TORTOISE. The two DTI acquisitions were averaged and diffusion tensor parameters (FA, 
MD, DA and DR) were generated. Each subject’s averaged B0 volume was co-registered to 
its T1 structural image using linear and nonlinear co-registration algorithms in AFNI. The 
same procedure was used for all registration steps. All T1 images were co-registered to a 
1x1x1 mm3 MNI152 T1-weighted standard template. The FA, MD, DA, and DR images of 
each subject were warped using the same transformations. As a final step, co-registered FAs 
were averaged, and all FAs were again co-registered to this mean FA. These transformations 
were then applied to co-registered MD, DA, and DR images to further improve co-
registration. A threshold of FA > 0.2 was set so as to only include white matter in the analysis 
(Mori & van Zijl, 2002). 
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Figure 5. Calculating intraindividual standard deviation (iSD). SDs were calculated for each of the six 30-trial 
administrations of the simple and choice reaction time tasks. The average SD was calculated across each of the 
three test sessions for both tasks. Finally the average SD was calculated across the three test sessions to obtain an 
overall iSD score for both tasks.  
 
Inferential statistical analyses. I conducted all of these analyses using SPSS (version 
25.0) with α set at .05, unless otherwise stated. 
Between-group differences. A series of independent sample t-tests investigated 
between-group differences in sample demographic characteristics (e.g., age, sex, highest level 
of education, household income) and cognitive performance (CAMCOG and MMSE scores, 
mean SRT and CRT values, and iSD SRT and CRT values). 
To identify clusters of significant between-group differences in white matter FA and 
MD, I used FSL-randomise to perform voxelwise comparisons. Monte Carlo simulations 
(Forman et al., 1995) helped control for Type I error. AFNI’s 3dFWHMx and 3dClustSim 
(v17.0.17) were used to calculate the minimum volume of clusters within each network mask 
for significance at voxelwise p < .01 and < .05 (Cox, 1996). I extracted the mean FA or MD, 
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as well as AD and RD, for all clusters with significant between-group differences in white 
matter FA and MD. 
Bivariate correlations. A series of bivariate correlational analyses, using Pearson’s 
coefficient, sought to identify predictor variables that would be used in subsequent regression 
modelling. Specifically, I correlated the mean DTI parameters (FA, MD, DA, DR) extracted 
from each cluster showing significant between-group differences with iSD for SRT and CRT, 
separately. I also considered correlations between those same clusters and participant 
demographic variables (viz., age, sex, highest level of education, household income). 
Regression models. A series of hierarchical regression models examined the utility of 
RTIIV (i.e., iSD for either SRT or CRT) for predicting white matter integrity. The outcome 
variable in each model was one of the DTI white matter indices (i.e., FA, MD, DA, or DR) 
that had been observed, at the previous step of the analysis, to correlate significantly with 
either simple or choice RTIIV. Each model consisted of three blocks of predictors. The first 
block contained sample demographic variables that correlated at p <. 10 with the DTI white 
matter indices identified by the bivariate correlational analyses. The second block contained 
either mean SRT or mean CRT, depending on whether SRT or CRT iSD was correlated at p < 
.10 with the outcome variable (i.e., the white matter index under consideration). The third 
block contained either SRT iSD or CRT iSD, again depending on whether SRT or CRT iSD 
was correlated at p < .10 with the outcome variable.  
Ethical Considerations  
 Ethical approval. Ethical approval for the parent study was obtained from the 
Human Research Ethics Committee (HREC) of UCT’s Faculty of Health Sciences 
(HREC/REF: 167/2014). See Appendix I for the original approval letter and subsequent 
updates. 
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Consent and confidentiality. As noted above, all participants were asked to read and 
sign an informed consent document at each of the screening sessions, and a similar document 
at the MRI scanning session. The first document briefly explained the purpose of the parent 
study, the study procedure, and the risks and benefits of participation. It also explained that 
participation was voluntary and that participants were free to withdraw from the study at any 
point. It stated that such withdrawal would not affect any existing or future GSH treatment. 
This document also provided the names and contact details of persons with whom 
participants could communicate should they have any questions or concerns about the study. 
In addition to the above information, the second document described the MRI procedure and 
outlined the potential risks of undergoing an MRI scan. Although AD patients are cognitively 
impaired, those in the mild-to-moderate stage of the disease are still able to make decisions 
(Kim, Caine, Currier, Leibovici, & Ryan, 2001). However, a relative or friend was also 
present during testing to ensure that consent was informed and voluntary. 
To ensure patient confidentiality, participants’ medical records were not removed 
from GSH and their names and medical histories were not discussed with anyone not 
involved in the study. To ensure confidentiality of the collected data, all computerised data 
were password protected. Data collected on the CANTAB device were kept inside a locked 
office, with password protection effected whenever the device was not in use. All hardcopy 
data were kept in a secure filing cabinet. 
Potential risks and discomfort. There were no direct physical, psychological, or 
social risks associated with participation. There were, however, several potential sources of 
discomfort. For instance, participants were required to travel to GSH for at least the 
neuroimaging session, and perhaps for as many as three test sessions in addition to that. 
Furthermore, the cognitive assessments they were required to complete were demanding and 
time-consuming. Some participants may have felt uncomfortable answering questions about 
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their declining cognitive status and performing tasks designed to challenge that status. They 
were, however, given regular breaks and were reminded that they could take as many breaks 
as needed in order to lessen the burden of completing the test session. 
Finally, the partially enclosed MRI scanning machine, as well as the loud noises the 
scanner makes, may have made some participants nervous. Participants were alerted to these 
aspects of the scan beforehand, and were assured that they could end the scan at any point 
should they feel too anxious to carry on. Participants were instructed verbally, as well as in 
the MRI consent form, to notify either the researcher or the MRI technician of any metal 
other than dental fillings they had in their bodies. Participants with certain metals that would 
be attracted to the magnetism of the MRI machine would have been excluded from the 
imaging component of the study. Participants were further reminded that they were free to 
withdraw from the study at any point if they felt uncomfortable and did not wish to 
participate further. 
Potential benefits and compensation. Participants were compensated ZAR70 (at the 
time of the study, approximately US$5.13) at each of the test sessions to compensate them for 
their travelling costs. They were also given a total of ZAR200 (at the time of the study, 
approximately US$14.65) at the end of the neuroimaging phase to compensate them for their 
travelling costs and effort. 
Results 
Sample Characteristics  
Analyses detected no significant between-group differences in age, sex distribution, or 
monthly household income distribution. On average, however, controls had completed 
significantly more years of formal education. They also achieved significantly higher 
CAMCOG-R and MMSE scores (see Table 1). 
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Preliminary Analyses: Between-group differences in predictor and outcome variables 
Extraction of iSDs. The first (mixed-effects) model identified sex, test order, trials, 
and test administrations as fixed effects that contributed significantly to SRT latency. The 
second (mixed-effects) model identified group membership, sex, household income, test 
order, trials, and test administrations as fixed effects that contributed significantly to CRT 
latency. 
I then ran two random coefficient models, one with SRT latency and the other with 
CRT latency as the outcome variable. All fixed effects identified by the two models above, as 
well as their higher-order interactions, were entered as predictors into each random 
coefficient model. Furthermore, both models included trials as a random slope. The 
standardised residuals from each of the random coefficient models were computed and then 
converted into T-scores. Using the compute variable function in SPSS, I entered the Z-scores 
as the target variable and then multiplied each score by 10 before adding 50 to the total score. 
This method, which is consistent with that used by Hultsch et al. (2000), Hultsch, 
MacDonald, and Dixon (2002) and Moy et al. (2011), helped partial out group and time-on-
task effects, and thus ensured that iSD was calculated on true error variance. 
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Table 1 
Descriptive Statistics and Between-group Differences: Sociodemographic variables and general 
cognitive functioning (N = 36) 
 Group  
 Controls AD Patients  
Variable (n = 20) (n = 16) t / 2 / z p ESE 
Age (years) 69.70 (7.13) 73.25 (6.18) 1.57 .125 -0.52 
Sex (M:F) 6:14 4:12 0.11 1.00 .739 
Education (years) 11.95 (2.67) 9.00 (2.25) -3.53 .001*** 1.03 
Income (1:2:3:4:5) 1:3:3:4:9 0:1:9:3:3 -7.8 .01 .465 
CAMCOG-R total score 92.45 (5.99) 67.94 (11.83) -7.55 < .001*** 1.61 
MMSE total score 27.75 (1.86) 22.19 (4.20) -4.93 < .001*** 1.34 
Note. For the variables Age, Education, Income, CAMCOG total score, and MMSE score, means are 
presented with standard deviations in parentheses. For the variable Sex, M = male and F = female. The 
variable Income refers to monthly household income; this was categorized on a 1-6 scale, where 1 = 
ZAR 500-999, 2 = ZAR 1000-2499, 3 = ZAR 2500-5499, 4 = ZAR 5500-9999 and 5 = ZAR 10000+. 
For each between-group comparison, degrees of freedom were 34, except CAMCOG-R total score 
(21.1) and MMSE total score (19.7). CAMCOG-R = Cambridge Cognitive Examination - Revised; 
MMSE = Mini-Mental State Examination; ESE = effect size estimate (for t, Cohen’s d, for chi square, 
ϕ, and for Mann-Whitney, Cohen’s r). 
*p < .05. **p < .01. ***p < .001. 
 
Between-group differences in RT variables. Regarding IIVRT values, analyses 
detected significant between-group differences on both the SRT and CRT tasks. In both 
cases, patients showed significantly more IIV in performance (see Table 2).  
Regarding mean RT values, analyses detected a significant between-group difference 
on the CRT task, but not on the SRT task. In both cases, however, the average response time 
of controls was faster than that of patients. 
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Between-task differences in IIVRT and mean RT. The descriptive statistics in Table 
2 show that, in both controls and patients, IIV on the CRT task was higher than that on the 
SRT task. Independent-samples t-tests indicated that this difference was statistically 
significant for controls, t(19) = 2.32, p = .01, but not for patients, t(15) = 0.65, p = .26. 
The descriptive statistics in that table also show that, in both controls and patients, 
mean RT latencies were slower on the CRT task than on the SRT task. Independent-samples 
t-tests indicated that this difference was statistically significant for patients, t(30) = 2.09, p = 
.045, and for controls, t(38) = 2.92, p = .006. 
 
Table 2 
 
  
Descriptive Statistics and Between-group Differences: Predictor variables (N = 36) 
  Group  
 Controls AD Patients  95% CI 
Variable (n = 20) (n = 16) t p Lower Upper 
iSD       
 SRT 8.36 (1.49) 10.30 (2.43) 2.95 .006** 0.61 3.28 
 CRT 8.88 (1.37) 10.63 (2.29) 2.85 .007** 0.51 3.00 
Mean RT       
 SRT 318.39 (35.11) 341.01 (58.03) 1.45 .157 -9.17 54.40 
 CRT 350.46 (34.31) 383.15 (56.05) 2.16 .038* 1.87 63.51 
Note. Data presented are means, with standard deviations in parentheses. For each between-group 
comparison, degrees of freedom were 34. iSD = intraindividual standard deviation; Mean RT = Mean 
reaction time across 180 trials of task performance; SRT = Simple Reaction Time task; CRT = Choice 
Reaction Time task; 95% CI = confidence intervals at the 95% level. All p-values are two-tailed. 
*p < .05. **p < .01. ***p < .001. 
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Voxelwise analyses. Regarding FA, initial voxelwise comparisons and post-hoc 
analyses detected two clusters where, on average, values were significantly lower in patients 
than in controls. These clusters corresponded to regions in (a) the R-ILF, and (b) the body of 
the corpus callosum (BCC; Figure 6). Further analysis detected no significant between-group 
differences in DA in these two regions, but significantly higher mean DR in patients than in 
controls in both. Table 3 gives the peak coordinates and size of each cluster, as well as the 
group mean FA, DA, and DR values. 
Regarding MD, initial voxelwise group comparisons and post-hoc analyses detected 
one additional cluster where, on average, values were significantly higher in patients than in 
controls. That cluster corresponded to a region in the genu of the corpus callosum (GCC; 
Figure 7). Further analysis of that region detected significantly higher mean DR in patients 
than in controls, but no significant between-group differences in DA. Table 4 gives the peak 
coordinates, as well as the group mean MD, DA, and DR values. 
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Table 3 
 Fractional Anisotropy: Size and peak coordinates (in MNI standard space) of regions showing 
significant between-group differences (N = 36) 
 
 Group  
 Controls AD Patients  95% CI 
Region 
(MNI peak coordinates) (n = 20) (n = 16) t p Lower Upper 
R-ILF (44, -35, -6)      
  FA 0.34 (0.01) 0.31 (0.01) 5.32 < .001*** 0.32 0.34 
  DA 0.28 (0.03) 0.27 (0.03) 1.18 .245 0.27 0.29 
  DR 0.21 (0.03) 0.24 (0.03) -2.68 .011* 0.21 0.23 
BCC (4, -27, 18)      
  FA 0.26 (0.03) 0.23 (0.02) 4.49 < .001*** 0.24 0.25 
  DA 0.20 (0.05) 0.21 (0.04) -1.16 .253 0.19 0.22 
  DR 0.27 (0.04) 0.31 (0.02) -4.29 < .001** 0.28 0.30 
Note. Data are group averages (SD) of the mean FA, DA, and DR in 8mm
3
 ROIs around the peak 
coordinates. For each between-group comparison, degrees of freedom were 34, except BCC-FA (32) 
and BCC-DR (28). MNI = Montreal Neurological Institute; R-ILF = right inferior longitudinal 
fasciculus; BCC = body of corpus callosum; FA = fractional anisotropy; DA = axial diffusivity; DR = 
radial diffusivity; CI = confidence intervals at the 95% level. All p-values are two-tailed. 
 
*p < 0.05. **p < 0.01. ***p < 0.001 
 
Table 4 
 Mean Diffusivity: Size and peak coordinates (in MNI standard space) of region showing significant 
between-group differences (N = 36) 
  Group  
 Controls AD 
Patients 
 95% CI 
Region 
(MNI peak coordinates) (n = 20) (n = 16) t p Lower Upper 
GCC (-5, 19, -1)      
  MD 0.22 
(0.03) 
0.25 
(0.03) 
-2.95 .006** -0.05 -0.01 
  DA 0.17 
(0.06) 
0.20 
(0.05) 
-1.51 .140 -0.06 0.01 
  DR 0.25 
(0.03) 
0.28 
(0.03) 
-2.78 .009** -0.05 -0.01 
Note. Data are group averages (SD) of the mean MD, DA, and DR in 8mm
3
 ROIs around the peak 
coordinates. For each between-group comparison, degrees of freedom were 34. MNI = Montreal 
Neurological Institute; GCC = genu of corpus callosum; DA = axial diffusivity; DR = radial 
diffusivity. 95% CI = confidence intervals at the 95% level. All p-values are two-tailed. 
 
*p < 0.05. **p < 0.01. ***p < 0.001. 
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Figure 6. Fractional anisotropy (FA): Brain regions where mean values were significantly 
lower in AD patients (n = 16) than in matched healthy controls (n = 20). Panel A highlights 
an area in the right inferior longitudinal fasciculus, and Panel B highlights an area in the body 
of the corpus callosum. In both panels, cross-hairs indicate peak coordinates. 
 
 
Figure 7.   Mean diffusivity (MD): An area in the genu of the corpus callosum where mean value 
was significantly higher in AD patients (n = 16) than in matched healthy controls (n = 20). Cross-
hairs indicate peak coordinates. 
 
 
55 
 
Main Analysis: Regression modelling 
Bivariate correlations between cognitive predictors and white matter outcome 
variables. The first series of correlational analyses (see Table 5) investigated associations 
between IIVRT (derived separately, as described earlier, for the SRT and CRT tasks) and FA 
(and corresponding DA and DR) values in the regions in which the voxelwise comparisons 
described above detected significant between-group differences. As the Table shows, the 
analysis detected significant associations between (a) FA in R-ILF and SRT iSD, (b) DA in 
R-ILF and SRT iSD, and (c) DA in R-ILF and CRT iSD. 
The second series of correlational analyses (see Table 5) investigated associations 
between IIVRT (the same variables as described above) and MD (and corresponding DA and 
DR) values in the regions in which the voxelwise comparisons described above detected 
significant between-group differences. As the Table shows, the analysis detected no 
significant correlations. 
Bivariate correlations between sociodemographic variables and white matter 
outcome variables. This series of correlational analyses (see Table 6) sought to identify 
possible confounding factors that should be entered into subsequent regression models. 
Hence, they investigated associations between a set of sociodemographic variables (age, sex, 
monthly household income, number of years of education, and group membership) and the 
white matter index values identified as being significant by the previous set of bivariate 
correlations. In this instance, I set the α level at < .10 to decrease the probability of making a 
Type I error. As the Table shows, the analysis detected a significant association between FA 
in R-ILF and years of education (r = .33, p = .051). Hence, I added the latter 
sociodemographic variable to the subsequent regression models. 
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Table 5 
 
Bivariate Correlations: Associations between measures of cognition (IIVRT) and indices of 
white matter integrity in regions that showed significant between-group differences (N = 36) 
  Outcome 
  Fractional Anisotropy 
Predictor Region (MNI peak coordinates) FA DA DR 
SRT iSD 
R-ILF (44, -35, -6) 
-.33 (.047) -.33 (.050) .27 (.116) 
 BCC (4, -27, 18) -.04 (.816) .13 (.461) .05 (.786) 
     
CRT iSD R-ILF (44, -35, -6) -.31 (.063) -.43 (.008) .22 (.190) 
 BCC (4, -27, 18) -.14 (.409) .16 (.338) .17 (.334) 
     
  Mean Diffusivity 
  MD DA DR 
SRT iSD GCC (-5, 19, -1) .01 (.965) .13 (.461) -.10 (.577) 
     
CRT iSD GCC (-5, 19, -1) .04 (.817) .09 (.618) -.02 (.927) 
Note. Data presented are Pearson product-moment correlation coefficients (r values), with 
associated p values in brackets. Statistically significant associations are marked in boldface 
font. SRT iSD = intraindividual SD on the Simple Reaction Time task; CRT iSD = 
intraindividual SD on the Choice Reaction Time task; FA = fractional anisotropy; MD = 
mean diffusivity; DA = axial diffusivity; DR = radial diffusivity.  
 
 
  
Table 6 
 
Bivariate Correlations: Associations between sociodemographic characteristics and indices 
of white matter integrity in regions that correlate significantly with IIVRT (N = 36) 
  Age Sex Income Education 
FA R-ILF -.07 (.680) -.03 (.874) 5.61 (.230) .33 (.051) 
DA R-ILF .06 (.749) -.00 (.988) 
0.988 
 
0.85 (.931) -.01 (.959) 
Note. Data presented are Pearson product-moment correlation coefficients (r values), with 
associated p values in brackets, except for the variable Income where the Kruskal-Wallis test 
statistic is presented, with associated p values in brackets.  Statistically significant 
associations are marked in boldface font. FA = fractional anisotropy; DA = axial diffusivity; 
R-ILF = right inferior longitudinal fasciculus. 
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Hierarchical regression models. Given the results of the series of bivariate 
correlations, I ran three hierarchical regression models, all related to outcome variables 
associated with FA as an index of white matter integrity. For each model, the first prediction 
block included only the sociodemographic variable (education) that was significantly 
correlated with the relevant white matter index. 
The first model sought to determine the degree to which SRT iSD predicted FA in R-
ILF (see Table 7). As the Table shows, at the second step I added mean SRT latency to 
education, and at the third step I added SRT iSD to the other two predictors. Overall, this 
model accounted for 12% of the variance in FA in R-ILF. None of the predictors entered at 
any of the steps made a unique, significant contribution to that variance, however.  
 
Table 7 
 
Regression Model 1: Standardized regression coefficients for SRT iSD as a predictor of 
fractional anisotropy (FA) in the right inferior longitudinal fasciculus (R-ILF; N = 36) 
 Block / Predictor b SE b β 
Step 1    
 Education 0.002 0.001 .33 
Step 2    
 Education 0.002 0.001 .32 
 Mean SRT latency -2.89 0.00 -.07 
Step 3    
 Education 0.002 0.001 .26 
 Mean SRT latency 6.26 0.00 .15 
 SRT iSD -0.003 0.002 -.37 
Note. The predictor Education refers to the number of years of formal education completed 
successfully. SRT = Simple Reaction Time task; iSD = intraindividual SD.  
Step 1:  ΔR2 = .11; ΔF(1, 34) = 4.11, p = .051. 
Step 2: ΔR2 = .01; ΔF(1,33) = 0.18, p = .674. 
Step 3: ΔR2 = .08; ΔF(1,32) =  3.21, p = .083. 
Total adjusted R
2
 for the model = .12. 
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The second model sought to determine the degree to which SRT iSD predicted DA in 
R-ILF (see Table 8). As the Table shows, the order in which predictors were added to this 
model was identical to that of the first model, described above. Overall, this model accounted 
for 3% of the variance in DA in R-ILF. Again, none of the predictors entered at any of the 
steps made a unique, significant contribution to that variance. 
The third model sought to determine the degree to which CRT iSD predicted DA in 
R-ILF (see Table 9). As the Table shows, at the first block of predictors I included the 
demographic variable (number of years of completed education) that was significantly 
correlated with the white matter indices, at the second step I added mean CRT latency, and at 
the third step I added CRT iSD. Overall, this model accounted for 24% of the variance in DA 
in R-ILF. Both mean CRT latency and CRT iSD made significant independent contributions 
to that variance. 
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Table 8 
 
Regression Model 2: Standardized regression coefficients for SRT iSD as a predictor of axial 
diffusivity (DA) related to fractional anisotropy (FA) in the right inferior longitudinal 
fasciculus (R-ILF; N = 36) 
 Block / Predictor b SE b β 
Step 1    
 Education -8.33 0.002 -.01 
Step 2    
 Education 0.00 0.002 -.03 
 Mean SRT latency 0.00 0.00 -.21 
Step 3    
 Education -0.001 0.002 -.09 
 Mean SRT latency 1.26 0.00 -.00 
 SRT iSD -0.004 0.003 -.35 
Note. The predictor Education refers to the number of years of formal education completed 
successfully. SRT = Simple Reaction Time task; iSD = intraindividual SD.  
Step 1: ΔR2 = .00; ΔF(1,34) = 0.003, p = .959. 
Step 2: ΔR2 = .04; ΔF(1,33) = 1.47, p = .233. 
Step 3: ΔR2 = .07; ΔF(1,32) = 2.62, p = .115. 
Total adjusted R
2
 for the model = .12. 
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Table 9 
Regression Model 3: Standardized regression coefficients for CRT iSD as a predictor of axial 
diffusivity (DA) related to fractional anisotropy (FA) in the right inferior longitudinal 
fasciculus (R-ILF; N = 36) 
Block / Predictor b SE b β 
Step 1    
 Education -8.33 0.002 -.01 
Step 2    
 Education 0.00 0.002 -.05 
 Mean CRT 
latency 0.00 0.00 -.35* 
Step 3    
 Education -0.001 0.001 -.12 
 Mean CRT 
latency 0.00 0.00 -.21 
  CRT iSD -0.005 0.002 -.38* 
Note. The predictor Education refers to the number of years of formal education completed 
successfully. CRT = Choice Reaction Time task; iSD = intraindividual SD. 
Step 1: ΔR2 = .00; ΔF(1,34) = 0.003, p = .959. 
Step 2: ΔR2 = .12; ΔF(1,33) = 4.52, p = .041. 
Step 3: ΔR2 = .12; ΔF(1,32) = 4.80, p = .036. 
Total adjusted R
2
 for the model = .24. 
*p < .05. 
 
Discussion 
The current study sought to determine whether changes in white matter micro-
structure, as measured by diffusion tensor imaging (DTI), contribute to intraindividual 
variability (IIV) on reaction time (RT) tasks. To answer this question, I gathered data from 
patients with mild-to-moderate Alzheimer’s disease (AD) and age-matched healthy controls. 
Cognitive test results indicated that IIV on both the simple and choice RT tasks (SRT 
and CRT, respectively) was higher in patients than in controls. Moreover, controls (but not 
patients) had significantly higher IIV on the CRT than on the SRT task. Finally, both patients 
and controls had significantly longer mean RT latencies on the CRT than on the SRT task. 
61 
 
DTI results indicated that, relative to values in controls, patients had significantly 
decreased white matter integrity in an area of the R-ILF, as well as in the body and the genu 
of the corpus callosum (BCC and GCC, respectively). 
Results from the study’s main analysis indicated that a loss of micro-structural white 
matter integrity was significantly associated with increased IIV. Specifically, fractional 
anisotropy (FA) in an area of the R-ILF was significantly negatively correlated with 
intraindividual standard deviation (iSD) on the SRT task, while axial diffusivity (DA) in the 
same brain region was significantly negatively correlated with iSD on both the SRT and CRT 
tasks. Moreover, in the same brain region, higher IIVRT on the CRT task predicted lower DA, 
a result that held over and above mean CRT latencies. 
Group Differences in Mean RT Latencies and IIVRT 
The current results suggest that IIVRT may be able to detect subtle cognitive changes 
that group-mean measures do not. For instance, in contrast to the absence of significant 
between-group differences in terms of mean RT latency on the SRT task, patients had 
significantly higher iSDs than controls on the same task. Hence, IIVRT may be able to detect 
cognitive decline when the level of impairment is not severe enough to affect mean-level 
measures significantly.  
In contrast to the current findings, previous studies have reported significantly longer 
mean RT latencies in patients than controls on SRT tasks (Anstey et al., 2007; Hultsch et al., 
2000). One potential reason for these discrepant findings is that, whereas the current patient 
sample consisted of individuals with mild-to-moderate AD, Hultsch et al. (2000) reported on 
patients with mild dementia (either AD or vascular dementia) and Anstey et al. (2007) 
included a sample of older adults with mild cognitive disorders (diagnosed by consensus 
clinical judgement as having either mild cognitive impairment, age-associated memory 
impairment, age-associated cognitive decline, or mild neurocognitive disorder). Two recent 
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reviews have suggested that AD pathology begins in deep brain regions (especially limbic 
and temporal lobe grey and white matter) and eventually extends into most cerebral grey and 
white matter as the disease progresses (Acosta-Cabronero & Nestor, 2014; Wang & Yu et al., 
2015). Hence, one might expect that this pattern would hold for patients in the current 
sample. On the other hand, the neural damage within the clinical samples in the Hultsch et al. 
(2000) and Anstey et al. (2007) studies is likely to have been less circumscribed given that 
their patients’ diagnoses likely encompassed a wider range of primary cognitive deficits. 
Because performance on RT tasks is known to rely on a diffuse collection of brain regions 
(especially within the frontal, parietal, and occipital lobes) involved in sustained and focused 
attention (Baddeley, Baddeley, Bucks, & Wilcock, 2001; Levinoff, Saumier, & Chertkow, 
2005), it is possible that between-study discrepancies in results could be accounted for by 
differences in the brain regions affected in each clinical sample. More specifically, it is 
possible that the current clinical group performed similarly to the control group on the SRT 
task because the brain mechanisms required for performance were relatively intact compared 
to those of the clinical groups used in the other two studies.  
Although the current analyses detected no significant between-group difference in 
mean latency on the SRT task, similar to those of Hultsch et al. (2000) and Anstey al. (2007), 
they did detect such differences on the CRT task (patients performed more poorly than 
controls). Performance on CRT tasks involves a decisional component that is not needed 
during performance on SRT tasks (Levinoff et al., 2005). Furthermore, stimulus processing 
during performance on a CRT task requires additional visuospatial attention compared to that 
on a SRT task, as participants need to visually monitor several places for the appearance of 
the target stimulus (Tuch et al., 2005). Hence, the currently observed data pattern might be 
accounted for by an increase in cognitive load, requiring recruitment of additional brain 
mechanisms, during performance on the CRT task. In other words, one might argue that 
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although participants in the current patient group had sufficient cognitive and neural capacity 
to perform at a similar level to controls on the SRT task, this capacity was depleted by the 
increased demands of the CRT task. The differences in findings between the current study 
and those of Hultsch et al. (2000) and Anstey et al. (2007) could therefore be due to a 
combination of differences in samples used, and the relatively increased cognitive load of 
CRT tasks compared to SRT tasks.  
Regarding IIVRT, the current findings are consistent with those of several others 
reporting higher values in patients than in controls. For example, Hultsch et al. (2000) found 
that, compared to patients with arthritis and healthy controls, those with mild dementia had 
higher IIV on both SRT and CRT tasks. They also reported that, in the dementia group but 
not in the other two groups, IIV on the SRT task was significantly smaller than that on the 
other cognitive tasks. Similarly, Gorus et al. (2008) found that, compared to patients with 
MCI and healthy controls, patients with AD had higher IIVRT. They also reported, similar to 
Hultsch et al. (2000), that IIV increased with task complexity, and that this increase was 
greater in the AD group than in the other two groups. Taken together, the findings from these 
two studies suggest that (a) IIV is higher in tasks with a higher cognitive load, and (b) this 
difference may be more pronounced in those with more severe neurological impairment. 
In those respects, the current findings differ somewhat to those of Hultsch et al. 
(2000) and Gorus et al. (2008). Here, controls but not patients had significantly higher IIV on 
the CRT task than on the SRT task. That is, in contrast to those previous studies, the current 
results suggest that IIV is higher in tasks with a higher cognitive load in neurologically intact 
individuals but not in neurologically impaired patients. This pattern of findings leads to the 
suggestion that IIV is only higher in tasks with a higher cognitive load when the brain 
mechanisms responsible for maintaining consistency in performance are intact. It is possible 
that when cognitive load increases, the demand on these mechanisms increases to a point 
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where they can no longer keep up, and consistency in performance drops. When these same 
brain mechanisms are damaged (as they might be, for example, in AD patients), the effect of 
cognitive load on IIV is decreased and a more uniform increase in IIV is seen across 
cognitive tasks as a consequence of that damage. 
Further to ways in which methodological choices might have contributed to between-
study discrepancies in findings, in the task used by Hultsch et al. (2000), but not in the 
current task, participants were presented with a warning stimulus prior to presentation of the 
target stimulus. It is possible that this warning stimulus had a greater effect on variability in 
the SRT task and that this effect was stronger in Hultsch et al.’s controls more than patients. 
Several studies have highlighted the role of a non-specific motor preparedness, as well as 
responding without fully analysing the stimulus, in producing the warning effect (Hackley & 
Valle-Inclán, 2003; Zeigler, Graham, & Hackley, 2001). In addition, the neural correlates of 
the warning effect in automated responses, such as an eye blink, are similar to those of 
purposeful responses such as that seen in RT performance (Zeigler et al., 2001). This 
suggests that the efficacy of the warning effect lies at least in part on priming automatic or 
reflexive responses. Accurate performance on CRT tasks such as the one used by Hultsch and 
colleagues requires relatively more reflective cognitive processing (including visual 
processing and motor responses) compared to performance on a similar SRT task. It is 
therefore possible that the introduction of a warning signal will disproportionately improve 
performance on SRT tasks compared to CRT tasks, possibly reducing variability on the SRT 
task to a greater extent. Furthermore, several studies into the neural and cognitive correlates 
of the warning effect have identified top-down attentional control networks and motor 
cortical areas as being involved in improving performance on warning trials (Boulinguez, 
Ballanger, Granjon, & Benraiss, 2009; Yoshida et al., 2013). These same attentional control 
networks appear to be compromised in dementia (Parasuraman & Haxby, 1993; Rapp & 
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Reischies, 2005; Rizzo et al., 2000). Hence, it is reasonable to speculate that dementia 
patients will not benefit as much as controls from a warning stimulus such as that used by 
Hultsch et al. (2000). 
Another explanation for the observed between-study differences is the number of RT 
trials used in the three studies. The current study had 30 test trials following the 10 practice 
trials, whereas Hultsch and colleagues’ study had 50 test trials following the 10 practice 
trials, and Gorus and colleagues’ study had 28 or 56 test trials and used replacement stimuli 
for trials where errors were made. The higher number of test trials in the other two studies 
may have introduced a fatigue effect, and that effect might have been stronger in patients than 
in controls. Cognitive fatigue has been linked to executive attention (Holtzer, Shuman, 
Mahoney, Lipton, & Verghese, 2010), and executive dysfunction is present in dementia 
patients (Baudic et al., 2006; Sgaramella et al., 2001; Sudo, Amado, Alves, Laks, & 
Engelhardt, 2017). Moreover, a tendency toward mental fatigue has been reported in several 
neurological conditions, including AD (for a review, see Chaudhuri & Behan, 2000). Hence, 
it is reasonable to speculate that Hultsch et al.’s and Gorus et al.’s patients became more 
fatigued than their controls during performance, and that this fatigue was more pronounced 
during the tasks with higher cognitive load, thus explaining (at least partially) the observed 
between-group and between-task discrepancies in IIV. 
Group Differences in Indices of White Matter Integrity 
DTI measures the movement of water molecules in and around organic tissue. 
Because white matter tissue is organized in a highly directional fashion, we expect to see 
highly directional (anisotropic) diffusion of water molecules in healthy white matter. DTI 
yields two main determinants of white matter integrity: mean diffusivity (MD) and fractional 
anisotropy (FA). MD represents the mean diffusion of water molecules in and around organic 
tissue in all directions. As such, higher MD values are indicative of more overall diffusion, 
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and hence of less healthy white matter. FA, on the other hand, represents the degree of 
anisotropy along the tissue fibre. In other words, it gives information on how water molecules 
are diffusing parallel to the tissue fibre. In healthy white matter, we expect the diffusion of 
water molecules to be highly anisotropic. Consequently, lower FA values are usually 
associated with less healthy white matter (Alexander et al., 2007).  
DTI measures water diffusion in all possible directions, as well as the correlations 
between directions. This information is used to construct a tensor matrix. Three eigenvectors, 
representing the principle directions of diffusion, are extracted from this matrix. The 
diffusion tensor of each tissue voxel is then comprised of the three eigenvalues associated 
with each eigenvector. The eigenvectors are termed λ1, λ2, and λ3, and correspond to overall 
parallel (λ1) and perpendicular (λ2 and λ3) displacement along the tissue. Parallel 
displacement is commonly termed axial diffusivity (DA), whereas perpendicular 
displacement is commonly termed radial diffusivity (DR; Alexander et al., 2007). Lower DA 
is associated with axonal damage, whereas higher DR is associated with demyelination (Gold 
et al., 2012; Song et al., 2002; Sun et al., 2006). 
Compromised white matter integrity in the corpus callosum. The current analyses 
suggested that FA was lower in the BCC, and MD was higher in the GCC, in AD patients 
than in healthy controls. These results support the idea that micro-structural white matter in 
the body and anterior parts of the corpus callosum is affected in mild-to-moderate AD. They 
are also consistent with those of several other studies reporting compromised micro-structural 
white matter integrity in the body and anterior parts of the corpus callosum of those with AD 
compared to healthy controls (see, e.g., Canu et al., 2013; Kim et al., 2015; Rémy et al., 
2015; Tang & Qin et al., 2017; Teipel et al., 2014; Wang & Wang et al., 2015).  
Regarding the GCC specifically, the current findings are consistent with previous 
investigations in showing higher MD values in this region in AD patients than in controls 
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(Alves et al., 2012; Chen et al., 2009; Rémy et al., 2015; Wang & Wang et al., 2015). 
However, the present results differ from previous studies in that the current analyses did not 
detect a significant between-group difference for FA in the GCC (Canu et al., 2013; Kim, et 
al., 2015; Liu et al., 2011; although see Chen et al. (2009), who also did not find such 
between-group differences). Because FA in white matter represents the degree of water 
diffusion along the axon, it is possible that the current analyses did not detect a significant 
between-group difference in FA in the GCC because the water diffusion in the direction of 
the axon was not sufficiently disrupted in the current AD sample to result in significantly 
lowered FA values (Alexander et al., 2007).  
The current analyses also detected significant between-group differences in DR, but 
not DA, in the same areas where group differences in FA and MD were found. Together, this 
pattern of results suggests that the observed between-group differences in the body and 
anterior parts of the corpus callosum might be a consequence of AD-related changes in 
myelin, as opposed to compromised axonal integrity. Previous studies have found between-
group differences in DA in the corpus callosum of those with AD or CSF biomarkers for AD 
compared to healthy controls or those with no such biomarkers, indicating AD-related 
changes in axonal integrity (Agosta et al., 2011; Molinuevo et al., 2014). Perhaps the type of 
damage (loss of myelin integrity or axonal degeneration) is dependent at least in part on the 
stage of the disease. For example, studies examining micro-structural white matter integrity 
in the corpus callosum of those with mild-to-moderate AD compared to healthy controls have 
found significant between-group differences in DR, but not DA, in the body, genu, and 
splenium (Alves et al., 2012; Canu et al., 2013). On the other hand, studies examining the 
same thing in those with moderate AD compared to healthy controls have found significant 
between-group differences in DA in the body, and in both DA and DR in the rostrum, genu, 
and splenium of the corpus callosum (Agosta et al., 2011; Wang & Wang et al., 2015).  
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Compromised white matter integrity in the R-ILF. The current analyses detected 
significant between-group differences in the R-ILF, with patient FA and DR values 
significantly lower than those of controls. These findings support the notion that the ILF, at 
least in the right hemisphere, is affected early in the AD process. 
Regarding FA, several studies have found significantly decreased values in the ILF 
bilaterally in patients with mild AD compared to those with aMCI/MCI or healthy controls 
(Li et al., 2018; Liu et al., 2011; Rémy et al., 2015; Teipel et al., 2014). Consistent with the 
current results, Lee et al. (2015) found significantly reduced FA in the R-ILF in those with 
mild AD compared to a group of healthy controls and those with MCI. Similarly, a 
longitudinal study following patients from the mild to moderate stages of AD also found that 
FA decreased in the R-ILF over the course of the disease progression (Kitamura et al., 2013). 
Regarding DR, the current finding is consistent with results of other DTI studies of 
AD patients. For instance, Alves et al. (2012) and Stricker et al. (2009) found increased DR, 
but not DA, in an area of the ILF in patients with mild AD compared to healthy controls.  
Moreover, the longitudinal study referred to above (Kitamura et al., 2013) found that 
decreased FA in the R-ILF over the course of progression from mild to moderate AD was a 
consequence of changes in DR and not in DA. These findings differ somewhat from those of 
Agosta et al. (2011) and Pievani et al. (2010), both of whom found significantly decreased 
DA and DR in the ILF in patients with mild-to-moderate AD compared to healthy controls. 
Some of these differences in results could be due to the disease stage, with DR being affected 
early on in the disease process, and DA becoming affected later on. 
It is also possible that some of these cross-study differences are related to differences 
in analytic techniques between the studies. Three main data analysis techniques are used in 
region-specific DTI investigations: ROI, voxel-based (VBA), and tract-based spatial statistics 
(TBSS). In the current study, VBA identified clusters of significant between-group 
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differences in white matter FA and MD. This method is similar to the TBSS methods used by 
Agosta et al. (2011), Alves et al. (2012), and Stricker et al. (2009) - both take into account all 
brain white matter, identifying only those regions where there are significant between-group 
differences for subsequent statistical analyses. Although these two methods reduce bias by 
not relying on a priori specified brain regions, their results may be biased because they 
exclude brain regions that do not meet the (admittedly somewhat arbitrary) statistical 
threshold of significance. On the other hand, ROI analyses such as that used by Kitamura et 
al. (2013) and Pievani et al. (2010) examine white matter in pre-defined white matter tracts, 
eliminating the possibility of finding between-group differences in non-specified tracts 
(Soares et al., 2013).  
In addition to the above, whole-brain analysis techniques such as VBA and TBSS 
generate a series of coordinates where clusters of unhealthy white matter have been 
identified. These coordinates are then used to determine which white matter structures are 
affected. As such, the results of whole brain analysis techniques only tell us about the 
structural integrity of a small cluster of brain tissue within the identified white matter 
structure.  On the other hand, ROI analysis is based on the a priori specification of white 
matter tracts using seeds and target regions of interest. The results of ROI analyses help 
determine whether or not the specified tracts are affected by measuring the mean DTI indices 
(including FA and MD) of the entire tract. Hence, studies reporting results based on ROI 
analysis typically include a larger area of affected white matter compared to studies using 
whole-brain analysis methods. As such, the differences in findings between the current study 
and those of previous studies could be due, at least in part, to differences in data analytic 
techniques.  
Nonetheless, the involvement of the ILF is not surprising given this brain region has 
been implicated in a number of functions known to be affected in AD. For example, a recent 
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study highlighted the role of the ILF in semantic autobiographical memory (Hodgetts et al., 
2017), a key component of the memory loss observed from the early stages of AD (Kirk & 
Berntsen, 2018). The ILF has also been implicated in the semantic language system (Panesar, 
Yeh, Jacquesson, Hula, & Fernandez-Miranda, 2018), visual memory (Shinoura et al., 2007), 
emotional memory, as well as spatial awareness and visual object location (Grilli, 
Woolverton, Crawford, & Glisky, 2018; Latini et al., 2017), all of which are affected in the 
early stages of AD (Adlam, Bozeat, Arnold, Watson, & Hodges, 2006; Giffard, Laisney, 
Desgranges, & Eustache, 2015; Guariglia, 2007; Joubert et al., 2010; Kessels, Feijen, & 
Postma, 2005; Mårdh, Nägga, & Samuelsson, 2013; Tchakoute, Sainani, & Henderson, 
2017). 
Interim summary. Overall, the current DTI data support the proposal that there are 
micro-structural white matter changes in the early and moderate stages of AD, and that these 
changes are primarily due to disruptions in myelin integrity. Moreover, the results suggest 
that specific major white matter tracts (viz., those found in the corpus callosum and the 
inferior longitudinal fasciculus) are more heavily involved in the AD process than others. 
There are, however, a number of discrepancies between the current findings and those of 
previous studies, highlighting the importance of further examination of the micro-structural 
white matter changes seen in AD. Specifically, in order to reconcile differences in findings 
relating to DA and DR, more studies are needed to examine the role of myelin versus axonal 
degeneration in the early stages of AD. In addition, more research is needed into the specific 
areas of micro-structural white matter changes in AD, and how these changes progress over 
the course of the disease.  
Associations between Micro-structural White Matter Changes and IIV 
The current results are consistent with those reported in several previous studies 
suggesting a statistically significant relationship between IIV and some measure of micro-
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structural white matter integrity in healthy adults (see, e.g., Grydeland et al., 2013; Lin et al., 
2014; Moy et al., 2011). One of the main findings emerging from the current analyses was an 
association between IIVRT and DA (but not DR) in the R-ILF (i.e., higher IIVRT on the CRT 
task was correlated with lower DA in the R-ILF). As mentioned previously, lower DA values 
have been linked to disruptions in axonal integrity, whereas higher DR values have been 
linked to disruptions in myelin integrity. Thus, the current finding of a negative association 
between DA in the R-ILF and IIVRT suggests that, in the current sample, changes in IIV 
might be due to disruptions in the integrity of axonal structure rather than that of myelin.  
Previous studies have found that age-related increases in IIVRT were associated with 
decreased DR and DA in the main white matter fibre tracts. In their cross-sectional study of 
healthy adults aged between 22 and 88 years, Moy et al. (2011) found that an age-related 
increase in IIV was significantly associated with decreased FA and increased MD and DR in 
the main white matter tracts, but was not significantly associated with DA in any white matter 
tract. However, in their study of healthy adults aged between 20 and 83 years, Fjell, Westlye, 
Amlien, and Walhovd (2011) found that age mediated the relationship between IIV and DR 
in approximately 42% of the skeleton voxels, and that the same mediation was present for 
DA in 26% of the skeleton voxels.  
These cross-study differences in results are suggestive of the fact that the nature of the 
relationship between IIV and micro-structural white matter changes depends, at least 
partially, on the population being studied. For example, although AD is associated with 
disruption of both myelin and axonal integrity, several studies have argued that axonal 
disruption is the primary mechanism of white matter change in the disorder (Amlien & Fjell, 
2014; Huang, Friedland, & Auchus, 2007; Skillbäck, Zetterberg, Blennow, & Mattsson, 
2013; Stokin et al., 2005). Hence, it is possible that the current observations of an association 
between DA and IIV, in the absence of any association between DR and IIV, arose because 
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this sample included individuals with AD, and that IIV increased in patients as a result of 
disruptions to axonal integrity that were present as part of the disease process. In further 
support of this interpretation, demyelination is the primary mechanism of white matter 
disruption in normal aging (Bartzokis, 2004), and the results reported by Moy et al. (2011) 
and Fjell et al. (2011) suggest that age-related increases in IIV are primarily associated with 
decreases in myelin integrity.  
Considering the above, the currently observed pattern of data may be indicative of a 
marker of pathological white matter changes that are independent of the usual age-related 
white matter changes. More specifically, the current analyses detected associations between 
IIV and DA in the R-ILF, but no such associations in any other brain regions. Analyses also 
did not detect any associations between IIV and DR. The R-ILF has consistently been 
implicated in AD (see, e.g., Kitamura et al., 2013), and AD has consistently been associated 
with disruptions in axonal integrity (indexed by DA; see, e.g., Amlien & Fjell, 2014 and 
Skillbäck et al., 2013). Conversely, the ILF has not been implicated in the normal aging 
process, and white matter disruption during normal aging is thought to reflect a loss of 
myelin, as opposed to axonal integrity. Although tentative, and in need of further study, this 
suggestion lends support to the idea that IIV may be a useful tool in detecting neuropathology 
specific to patients with AD.  
It is also possible that the current pattern of data may reflect characteristics of the 
tasks used in this study. Data from Tamnes et al. (2012) suggest that tasks demanding a 
higher cognitive load rely on different white matter mechanisms than tasks with relatively 
less onerous requirements. Using a speeded version of the flanker task
2
, they found that FA 
                                                             
2 This task requires participants to respond to the presence of a target arrow in the middle of a screen, 
bordered by two “flanker” arrows on either side. Participants must indicate whether the target arrow is pointing 
left or right. On congruent trials, the flanker arrows are both pointing in the same direction as the target arrow. 
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and DA were associated with IIVRT on the congruent trials only, whereas MD and DR were 
associated with IIVRT on both congruent and incongruent trials. This pattern of data suggests 
that better overall white matter integrity underlies more consistent performance, but that 
when a task requires more attentional control and more complex cognitive processing (i.e., 
when it is of a higher cognitive load), myelin integrity plays a more important role in 
performance consistency than axonal integrity does. Hence, it is possible that the current 
analyses detected an association between DA and IIVRT in the absence of any associations 
between DR and IIVRT due to the fact that the current RT tasks were of relatively low 
cognitive load and thus relied less heavily on myelin integrity.  
Intraindividual variability and micro-structural white matter in Alzheimer’s 
disease. The current results are partially consistent with those of a previous study examining 
associations between white matter volume loss and IIVRT in a sample of early-stage AD 
patients and healthy controls (Jackson et al., 2012). Those authors found a significant 
negative correlation between IIVRT and white matter volume in the superior frontal gyrus, 
posterior cingulate, precuneus, and ventral and dorsolateral PFC. The current study extends 
those findings to micro-structural white matter integrity in AD patients. 
There are, however, a number of differences between the current findings and those of 
Jackson and colleagues. The latter found associations between IIVRT and white matter 
integrity in several brain regions, whereas the current analyses detected a significant 
association between IIVRT and white matter integrity in only one brain region. The most 
obvious way to account for these different findings relates to differences in analytic approach. 
                                                                                                                                                                                             
On incongruent trials, the flanker arrows are pointing in the opposite direction. During the speeded version of 
this task, participants are instructed to respond as quickly as possible. Hence, accurate and rapid performance 
(on the incongruent trials, especially) is thought to demand a higher cognitive load and to require additional 
cognitive processes (e.g., inhibition and top-down attentional control). 
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Jackson and colleagues used measures of regional white matter volume in several regions of 
interest, determined on the basis of brain regions known to be involved in the default-mode 
network (DMN), which has previously been implicated in IIV (Kelly et al., 2008). In 
contrast, in the current study I first performed voxelwise group comparisons to determine 
brain regions with significantly lower FA or significantly higher MD in patients compared to 
controls. Subsequent analyses then included only those areas where significant between-
group differences had been detected. I followed this analytic plan for both practical and 
theoretical reasons. First, this method cut down significantly on imaging analysis time. 
Moreover, the aim of the present study was to determine whether IIV was associated with 
changes in micro-structural white matter and whether these micro-structural changes were 
indicative of pathological brain changes as they might appear in AD patients. Hence, it made 
theoretical sense to first identify brain areas where pathological changes were present, and to 
then assess relations between IIV and micro-structural white matter within these areas. The 
fact that my analyses did detect an association between IIVRT and white matter integrity in 
one of these brain regions suggests that increased IIV in the current sample may indeed be 
related to pathological changes in white matter micro-structure. 
A second possible reason for the differences between the current findings and those of 
Jackson et al. (2012) relates to the tasks used in each study. In their study, Jackson and 
colleagues obtained a measure of IIVRT from three attentional control tasks, whereas in the 
current study I obtained a measure of IIVRT from simple and choice RT tasks. As noted 
earlier, Tamnes et al. (2012) suggest that performance on tasks requiring more attentional 
control relies more heavily on white matter integrity. If this is the case, one would expect to 
find stronger associations between IIV and white matter integrity on such tasks than one 
would on tasks requiring less attentional control. The pattern of findings in the current study 
supports that speculation. To wit, although the current analyses detected significant 
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correlations between IIV (on both the SRT and CRT tasks) and measures of micro-structural 
white matter integrity, regression modelling showed that only IIV on the CRT task was able 
to predict changes in micro-structural white matter integrity. CRT tasks are more 
attentionally demanding than SRT tasks, and involve a degree of inhibition not needed in 
SRT tasks (Burle, Vidal, Tandonnet, & Hasbroucq, 2004; Tuch et al., 2005). 
Functional neuroanatomy of the ILF. One of the major findings of the current 
analyses was that higher IIVRT on the CRT task predicted lower DA in the R-ILF, over and 
above the effect of mean CRT latency. To better interpret this finding, it is important to look 
into the structural and functional role of the inferior longitudinal fasciculus.  
The inferior longitudinal fasciculus is one of the major occipito-temporal connections, 
although its exact anatomy and functional role remain under investigation (Ashtari, 2012). 
For example, although several early studies indicated that the ILF has structural connections 
to occipital and temporal regions, two recent studies have differed in their conclusions 
regarding its hemispheric lateralization. In their analyses of DTI data from a sample of 24 
healthy adults, as well a post-mortem examination of 15 brains, Latini et al. (2017) found that 
the right ILF had more structural connections to other brain regions than did the left ILF. 
Panesar et al. (2018) reported a directly contrasting result, however: They used deterministic 
generalised Q-Sampling Imaging on 30 healthy adults, and found comparatively more 
structural connections between the ILF in the left hemisphere and other brain regions. 
Similarly, studies have differed in their conclusions regarding the functional role of the ILF. 
Some have implicated it in the semantic language system and in facial recognition (Panesar et 
al., 2018), whereas others have highlighted its role in visual, emotional, and semantic 
autobiographical memory (Hodgetts et al., 2017; Latini et al., 2017; Shinoura et al., 2007). 
Because IIV is higher on tasks tapping into attentional control, and on tasks with a 
higher cognitive load, one might expect associations between white matter integrity in the 
76 
 
ILF and IIVRT if that brain region played an important role in attentional control or higher-
order cognitive functioning. However, several studies examining the neural correlates of 
attentional control have found frontal and parietal (rather than occipital and temporal) regions 
to be associated with attentional control (Berry, Sarter, & Lustig, 2017; Wang et al., 2010). 
Similarly, resting state fMRI studies suggest the ILF is not a part of the task-related 
attentional network (Kelly et al., 2008).  
Several studies have, however, found an association between the structural integrity 
of the ILF and various aspects of visual processing, such as spatial awareness, objection 
location, and attentional shifts during visual perceptual processing (see e.g., Latini et al., 
2017; Shinoura et al., 2007; Shinoura et al., 2009). Of note here, then, is that performance on 
the RT tasks used in the current study relies in part on these visual processes. On both the 
SRT and CRT tasks, participants had to visually monitor the screen for the presence of the 
target stimulus (e.g., on the CRT task, participants had to identify the correct position of the 
target stimulus from amongst five possible locations, and had to shift their attention to the 
correct location in order to respond accurately). It is therefore possible that the current 
analyses detected an association between micro-structural white matter integrity in an area of 
the R-ILF and IIV on the RT tasks because of the role the ILF plays in visual processing. 
The above suggestion is supported by the fact that white matter integrity in the R-ILF 
predicted IIV on the CRT, but not the SRT. Because performance on the CRT task relies to a 
greater extent on these visual processes, one would expect to see a more robust relationship 
between white matter integrity in an area underlying these processes and IIV on that task. 
This proposal is consistent with findings from a prior study that examined the relationship 
between IIV on a CRT task and micro-structural white matter integrity in a group of healthy 
young adults. Tuch et al. (2005) found that IIV was significantly associated with the integrity 
of various white matter pathways supporting visuospatial attention, but was not associated 
77 
 
with integrity of white matter pathways supporting motor functions or with integrity of the 
corpus callosum.  
Limitations and Directions for Future Research  
The following limitations must be borne in mind when evaluating this study’s 
findings. First, the current results might have been confounded by the presence of 
unmeasured vascular pathology in the sample. Although eligibility criteria specified that 
individuals with a known history of stroke and other neurological disorders that impact on 
white matter integrity would be excluded from participation, the clinical group included 
patients diagnosed with mixed dementia (i.e., concurrent Alzheimer’s and vascular 
dementia). Furthermore, age-related vascular changes are common in those with Alzheimer’s 
disease (frequently at sub-clinical levels) as well as in healthy older individuals (Gorelick et 
al., 2011; Rincon & Wright, 2013). Hence, it is not clear whether the observed associations 
between IIVRT and micro-structural white matter integrity are strictly related to the white 
matter changes seen in AD and normal aging, or whether a loss of white matter integrity as a 
result of vascular pathology played a role.  
A second general limitation relates to the nature of the cognitive measures and the 
way in which they were used. Both the SRT and CRT tasks have a relatively low cognitive 
load compared to the executive function and attention control tasks used by other researchers 
(e.g., Jackson et al., 2012; Tamnes et al., 2012), and they were administered multiple times 
over several test sessions. These characteristics of the tasks and the procedure could have 
resulted in boredom and a lack of task engagement, especially in higher-functioning 
participants. Previous studies suggest that a lack of task engagement results in slower RT 
latencies and artificially increased IIV (Garrett, MacDonald, & Craik, 2012; Pan, Shell, & 
Schleifer, 1994; Wang, Ding, & Kluger, 2014). Moreover, the SRT task was always 
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administered before the CRT task. Hence, lack of task engagement and fatigue effects might 
have had disproportionate effects on mean RT latencies, as well as IIVRT, for the CRT task. 
A third general limitation relates to sample size. Although several published studies in 
this field have used samples smaller than the current one (see, e.g., Kim et al., 2015; Lin et 
al., 2014; Rémy et al., 2015), the current N of 36 means one has to be cautious in making 
strong inferences on the basis of, or generalizing substantially from, the current results. A 
related limitation is that, because analyses combined data from the clinical and control groups 
in order to increase statistical power, it was not possible to engage in meaningful examination 
of between-group differences in the magnitude of association between micro-structural white 
matter integrity and intraindividual variability. Hence, the current analyses do not allow 
comment on whether the observed associations between IIV and micro-structural white 
matter integrity are driven more strongly by the clinical group or by the control group, or 
whether each contributed relatively equally. 
In addition to the above limitations, the use of DTI, and interpretation of DTI-based 
data, requires some critical thought. Although advances have been made in the use of this 
imaging method for measuring disruptions in white matter integrity, several authors still 
advise caution when interpreting axonal and myelin integrity on the basis of such measures 
(see, e.g., Alexander et al., 2007; Soares et al., 2013). There are multiple reasons this caution 
is warranted. First, the presence of crossing white matter tissue fibres in numerous brain 
regions makes it difficult to accurately determine whether disruptions are due to axonal or to 
myelin degeneration (Assaf & Pasternak, 2008; Hagmann et al., 2006; Mori & Zhang, 2006; 
Winklewski et al., 2018). Second, both myelin and axonal degeneration are present in several 
different diseases, and the mechanisms of degeneration are varied. For example, several 
studies have highlighted the importance of interactions between myelinated and unmyelinated 
axons, and axonal disruption has been shown to occur secondarily to disruptions in myelin 
79 
 
integrity (Beirowski, Babetto, & Wrabetz, 2016; Klingseisen & Lyons, 2018; Nguyen et al., 
2009; Popko, 2010). On the other hand, one study (a mouse model of myelin-related disease) 
showed that demyelination does not necessarily lead to axonal degeneration (Smith, Cooksey, 
& Duncan, 2013). Hence, caution is warranted in concluding that the observed associations 
between IIVRT and  micro-structural white matter integrity are due purely to disruptions in 
axonal integrity, as it is possible that disruptions in axonal integrity in the current sample are 
related to or caused by disruptions in myelin integrity.  
A further limitation relates to the increased possibility of Type II error when using 
voxelwise between-group comparisons. In other words, it is possible that some brain regions 
with decreased white matter integrity in patients were not detected as they did not survive the 
statistical cluster thresholds of p < .01 and p < .05. 
To address these limitations, and to thereby allow firmer conclusions regarding 
associations between IIV and micro-structural white matter integrity, future studies should: 
(a) include separate clinical and control groups, taking care to exclude participants 
with vascular pathology. Although Jackson et al. (2012) attempted this strategy in their study, 
they also used a relatively small sample of AD patients (n = 33), and may therefore have 
missed significant between-group differences in their analyses;  
(b) use longitudinal studies of both AD patients and healthy controls to further 
examine the exact associations between IIVRT and micro-structural white matter integrity, in 
terms of both axonal and myelin disruption;  
(c) use more engaging tasks and ensure that these tasks are counter-balanced in their 
presentation; and 
(d) ensure their investigations are adequately powered by including larger numbers of 
participants. 
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In addition to the above recommendations, it would be interesting to see whether the 
observed associations between IIVRT and micro-structural white matter integrity remain when 
IIV is measured over a single time-frame of minutes or hours. I calculated IIV in the current 
study using RT measures obtained over six administrations spanning three test sessions. IIV 
measured in macro-time compared to that measured over a single time-frame of minutes or 
hours (micro-time) provides a more reliable measure of variability (Ram & Gerstorf, 2009). 
IIV measured in micro-time, however, is more easily obtained and thus might be a more 
fruitful avenue in investigating the clinical utility of IIV. To date, there is only one published 
study examining associations between IIVRT in micro-time and white matter integrity in a 
sample of AD patients and matched healthy controls. That study found no significant 
between-group differences in terms of this association (Jackson et al., 2012). As mentioned 
previously, however, those authors used a small sample and examined white matter volume 
as opposed to micro-structural white matter integrity.  
Summary and Conclusion  
Despite several methodological limitations, the current study provides evidence for an 
association between intraindividual variability in reaction time and micro-structural white 
matter integrity in older adults, including those with mild-to-moderate Alzheimer’s disease. 
The major findings were that there were significant associations between intraindividual 
variability on both reaction time tasks (simple and choice reaction time) and measures of 
micro-structural white matter integrity. Furthermore, higher intraindividual variability on the 
choice reaction time task predicted decreased micro-structural white matter integrity in the 
right inferior longitudinal fasciculus over and above mean choice reaction time latency. 
These results suggest that further investigation into these associations (e.g., longitudinal 
designs focusing specifically on whether intraindividual variability in cognitive performance 
can predict pathological changes in white matter) might be a fruitful avenue for future 
81 
 
research. Such studies will shed light on the possible diagnostic utility of intraindividual 
variability measures for detecting pathological brain changes during the early stages of age-
related degenerative diseases, when treatments and interventions are most likely to be 
effective. 
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Appendix A 
Participant Information Sheet  
 
PARTICIPANT INFORMATION LEAFLET 
 
 
TITLE OF THE RESEARCH PROJECT: Intraindividual Variability in the Progression of Alzheimer’s disease: A 
longitudinal trajectory of cognitive decline 
 
PROTOCOL NUMBER: HREC/REF: 167/2014 
 
PRINCIPAL INVESTIGATOR: Mr. Bjorn U. Christ 
 
ADDRESS:   Department of Psychology, PD Hahn Psychology Building, University Avenue, 
University of Cape Town, Rondebosch, Cape Town, 7701 
 
CONTACT NUMBER: +27 72 0710 346 
 
I am inviting you to participate in a research project that looks at how memory and other mental 
functions change with time. Please take some time to read the information presented in this 
information leaflet, because it explains the details of this project so that you can understand what this 
project is about. If you have any questions about this project, or if you want more information, please 
feel free to ask me (or your doctor at the memory clinic). It is very important that if you decide to 
participate in this study that you understand what this study is about and that all of your questions are 
answered before you participate.  
 
Your participation is entirely voluntary - this means that you don’t have to participate if you don’t 
want to - and you are free to decline to participate.  If you say no, and don’t want to participate, then 
this will not affect you negatively in any way whatsoever. It will not affect any future medical 
treatment you may need, and it won’t affect your treatment that you currently receive. If you decide 
that you do not want to take part in the study anymore, even though you said that you did want to, you 
are welcome to stop participating. You can stop participating in this study at any stage of the study, 
and you do not have to a give a reason for stopping. If you do stop, it will not affect your future 
medical treatment.  
 
This study has been approved by the Research Ethics Committee of the Faculty of Health Sciences of 
the University of Cape Town. This means that all the parts of this study, for example its design, 
procedures, and the materials and equipment that are used for the research, have been evaluated by an 
administrative authority and found to be respectful of the feelings and rights of its research 
participants.  Furthermore, the study will be conducted according to the ethical guidelines and 
principles of the International Declaration of Helsinki, the South African Guidelines for Good Clinical 
Practice and the Medical Research Council (MRC) Ethical Guidelines for Research. These guidelines 
will ensure that this study upholds a range of research practices that are accepted all over the world to 
be fair and respectful towards participants. 
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The project is being run by the Applied Cognitive Sciences and Experimental Neuropsychology 
Testing (ACSENT) laboratory and the Divisions of Neurology and Geriatric Medicine in the 
Department of Medicine at the University of Cape Town. This means the project is supported and 
supervised by experienced and qualified researchers within the Psychology Department and the 
Department of Medicine at the University of Cape Town. Furthermore, I aim to recruit a total of 90 
people to take part in the study. This will happen over a period of 18 months. 
 
What is this research study all about?  
 
Some people develop memory problems as they get older. Many elderly people have mild memory 
difficulties.  However, in a few, the problem may be more severe. I am interested in finding out more 
about how the difficulties with memory and other higher brain functions change over time.  In order 
to do so, I should like to investigate the course of these changes using a small number of methods. 
These include questions you would need to answer about yourself and tests of memory and other 
higher brain functions.  
 
I am interested in testing people both with memory difficulties and those without, so that we can 
compare the two groups. In this way I might be able to better understand the progression of change in 
brain function associated with memory impairment. My research findings may aid in the early 
detection and treatment of these conditions and help improve the design of drug intervention trials 
associated with these conditions in the future. 
 
Procedures 
 
If you agree to take part in the study you will be required to partake in a short telephonic interview 
about your medical history. This is done to ensure you meet all the conditions required to enter the 
study. You will then be invited to visit our clinic on three separate days over a two week period.  At 
these visits to our clinic I shall: 
 
(1) interview your relative/friend (someone who knows you well) to find out whether he/she 
thinks you have any memory difficulties. 
 
(2) ask you to complete a short questionnaire about your mental and emotional functioning. 
 
(3) perform tests of your memory and other higher mental functions. These will be conducted in 
a quiet, relaxed atmosphere. I expect that these tests will be about an hour’s duration. 
However, there will be opportunities to rest in-between tests. 
 
The questionnaires and the tests will be administered during the first visit, however for the subsequent 
two visits you will only be required to complete the tests. After the three baseline visits I would like to 
re-assess your memory and other higher functions again after six months and twelve months, 
respectively, provided you continue to consent to participation in the study. 
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If I find that you or your relative/friend has a significant memory problem that is interfering with your 
daily living activities, we shall refer you to a Memory Clinic. Your permission will always be sought 
first. 
 
What will your responsibilities be? 
 
You will be required to attend the study visit at the appropriate time and to participate as fully as you 
can with the tests and questionnaires. You should answer the questions as fully and honestly as you 
can. If there are any questions that you cannot, or do not wish to answer, you should tell us so. 
 
Will you benefit from taking part in this study? 
 
You will receive little direct benefit from the study. However, you will undergo a range of cognitive 
tests. As previously indicated, we shall, with your permission, refer you to the appropriate medical 
services if any treatable abnormalities are found. 
 
Are there any risks in your taking part in this research? 
 
You may feel uncomfortable about answering some of the questions about yourself or your 
friend/relative. Some people don’t like talking, or knowing about, problems related to memory or 
thinking. You should feel free to mention your feelings or concerns to any member of the study team. 
 
If you do not agree to take part, what alternatives do you have? 
You are free not to participate in the study or to refuse parts of the study.  
 
Who will have access to your medical records? 
 
The information collected about you will be treated as confidential and protected.  If it is used in a 
publication or thesis, your identity will remain anonymous.  Only the direct study team will have full 
access to the information. If we need to refer you to a clinic for treatment, we will provide them with 
the relevant information needed to treat your condition.  
 
Will you be paid to take part in this study and are there any costs involved? 
 
You will not be paid to take part in the study but your transport costs will be covered for the study 
visit. You will be reimbursed for the sum of R50-00 at each visit to the research site. There will be no 
costs involved for you, if you do take part. 
 
Is there anything else that you should know or do? 
 You should inform your family practitioner or usual doctor that you are taking part in a 
research study.   
 You can contact me on 072 0710 346 if you have any further queries or encounter any 
problems. 
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 You can contact the Research Ethics Committee of the Health Sciences Faculty of the 
University of Cape Town 021-4066338 if you have any concerns or complaints that have not 
been adequately addressed by your study doctor. 
 You will receive a copy of this information for your own records. 
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Appendix B 
DSM-IV diagnostic criteria for dementia of the Alzheimer’s type 
 
Diagnostic and Statistical Manual of Mental Disorders, 4th ed., American Psychiatric Association, 
1994; p142. 
 
A. The development of multiple cognitive deficits manifest by both 
 
(1) memory 
impairment AND 
(2) one (or more) of the following cognitive disturbances: 
 
(a) aphasia (language disturbance) 
(b) apraxia (impaired ability to carry out motor activities despite intact motor function) 
(c) agnosia (failure to recognize objects despite intact sensory function) 
(d) disturbance in executive functioning (i.e. planning, organization, sequencing, abstracting). 
 
B. The cognitive deficits in criteria A1 and A2 each cause significant impairment in social 
or occupational functioning and represent a significant decline from a previous level of 
functioning. 
 
The deficits do not occur exclusively during the course of a delirium. 
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Appendix C 
Clinical Dementia Rating (CDR) 
 
Ref: Hughes CP et al. British Journal of Psychiatry 1982; 140: 566-572 
 
 
Impairment Level and CDR Score (0, 0.5,  1, 2, 3) 
 None 
 
0 
Questionable 
 
0.5 
Mild 
 
1 
Moderate 
 
2 
Severe 
 
3 
Memory No memory loss or 
slight inconsistent 
forgetfulness 
Consistent slight 
forgetfulness; partial 
recollection of 
events; "benign" 
forgetfulness 
Moderate memory 
loss; more marked 
for recent events; 
defect interferes 
with everyday 
activities 
Severe memory loss; 
only highly learned 
material retained; 
new material rapidly 
lost 
Severe memory loss; 
 
only fragments 
remain 
Orientation Fully oriented Fully oriented 
except for slight 
difficulty with time 
relationships 
Moderate difficulty 
with time 
relationships; 
oriented for place at 
examination; may 
have geographic 
disorientation 
elsewhere 
Severe difficulty 
with time 
relationships; 
usually disoriented 
to time, often to 
place 
Oriented to person 
only 
Judgment & 
Problem 
Solving 
Solves everyday 
problems & handles 
business & financial 
affairs well; 
judgment good in 
relation to past 
performance 
Slight impairment in 
solving problems, 
similarities, and 
differences 
Moderate difficulty 
in handling 
problems, 
similarities, and 
differences; social 
judgment usually 
maintained 
Severely impaired in 
handling problems, 
similarities, and 
differences; social 
judgment usually 
impaired 
Unable to make 
judgments or solve 
problems 
Community 
Affairs 
Independent 
function at usual 
level in job, 
shopping, volunteer 
and social groups 
Slight impairment in 
these activities 
Unable to function 
independently at 
these activities 
although may still 
be engaged in some; 
appears normal to 
casual inspection 
No pretense of 
independent 
function outside 
home 
 
Appears well 
enough to taken to 
functions outside a 
family home 
No pretense of 
independent 
function outside 
home 
 
Appears too ill to be 
be taken to functions 
outside a family 
home 
Home and 
Hobbies 
Life at home, 
hobbies, and 
intellectual interests 
well maintained 
Life at home, 
hobbies, and 
intellectual interests 
slightly impaired 
Mild but definite 
impairment of 
function at home; 
more difficult chores 
abandoned; more 
complicated hobbies 
and interests 
abandoned 
Only simple chores 
preserved; very 
restricted interests, 
poorly maintained 
No significant 
function in home 
Personal 
Care 
Fully capable of self-care Needs prompting Requires assistance 
in dressing, hygiene, 
keeping of personal 
effects 
Requires much help 
with personal care; 
frequent 
incontinence 
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Appendix D 
Study Flyer 
 
 
 
 
  
Memory Study! 
 Participate in research on memory 
Are you over 55 years old? 
Would you like to be part of a research 
project in Cape Town that studies how 
memory and other brain functions 
change with time? 
 
We are looking for people who may be 
experiencing memory difficulties (such 
as forgetting names of people, places, 
where you have put things, etc.). 
 
The Research 
We are interested in finding out more 
about how difficulties with memory and 
other higher brain functions change as 
people get older. 
 
The information may in the future aid 
earlier detection and improved 
management of memory problems. 
 
This study has been approved by the UCT/GSH 
Research Ethics Committee  
 
 
Image courtesy of Stuart Miles / FreeDigitalPhotos.net 
 
Benefits 
 
• You will be contributing to 
important research in the field of 
memory and aging 
• You will be compensated for your 
travel costs 
• A report will be sent to your GP on 
request 
 
ACSENT Laboratory 
Department of Psychology 
University of Cape Town 
 
 
 
122 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
Would you like to take part in an important research project on 
memory? 
 
 
The Procedure 
 The study will take place over 12 months. 
 You will visit us on a few occasions over the 12-month span. 
 Each visit will require you to complete a small number of tests and questionnaires 
 Each visit will range between 60 and 90 minutes. 
 You will be compensated for your travel costs. 
 Although we do not provide medication we shall advise your GP or refer you to a 
clinic if necessary. 
 
 
Please Note: All participation is voluntary and participants may withdraw at any 
stage. Confidentiality of all data is ensured 
 
 
 
Image courtesy of ratch0013 / FreeDigitalPhotos.net 
 
 
FOR ADDITIONAL INFORMATION 
OR TO SCHEDULE A PRE-
SCREENING APPOINTMENT 
PLEASE CONTACT:  
 
 
Bjorn Christ 
Cell: project number 
Email: project email 
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Appendix E 
MRI Scanning Protocol 
Scanning protocol – WMC and IIV in AD 
 
The time of each acquisition is called TA (total acquisition) 
 
Localizer  (TA: 0:54)  
 
T1 high resolution structural 
imaging:  MEMPRAGE_1mm_iso_iPATx3  (TA: 5:21)  (5:21 means 5 mins and 21 sec) 
 
Resting state: 
Field map:gre_field_mapping  (TA: 1:10) 
Resting state acquisition: ep2d_Resting  (TA: 6:08) 
 
Diffusion tensor imaging in AP direction: BME_DTI_30gr_4b0_2mm_ISO_52sl_AP 
(TA: 6:14) 
Diffusion tensor imaging in PA 
direction: BME_DTI_30gr_4b0_2mm_ISO_52sl_PA  (TA: 6:14) 
 
FLAIR for fluid attenuation using tirm:  t2_tirm_tra_dark-fluid  (TA: 4:32) 
3D Susceptibility weighted imaging (SWI3D): t2_swi3d_tra_p2_1.5mm  (TA: 4:54) 
 
Proton Density weighted sequence.  
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Appendix F 
Informed Consent Form  
 
TITLE OF THE RESEARCH PROJECT: Intraindividual Variability in the Progression of Alzheimer’s disease: A 
longitudinal trajectory of cognitive decline 
 
PROTOCOL NUMBER: HREC/REF: 167/2014 
 
PRINCIPAL INVESTIGATOR: Mr. Bjorn U. Christ 
 
ADDRESS:   Department of Psychology, PD Hahn Psychology Building, University Avenue, 
University of Cape Town, Rondebosch, Cape Town, 7701 
 
CONTACT NUMBER: +27 72 0710 346 
 
I am inviting you to participate in a research project. Please take some time to read the information 
presented here. It explains the details of the project. If there are any aspects of the project you do not 
understand, please do not hesitate to ask the study staff or doctor.  It is important that you are fully 
satisfied that you clearly understand what this research entails and how you could be involved.  Your 
participation in the study is entirely voluntary and you are free to decline to participate.  If you say no, 
this will not affect you negatively in any way whatsoever.  It will not affect any future medical 
treatment you may need. You are also free to withdraw from the study at any point, even if you did 
initially agree to take part. You do not have to give a reason for withdrawing. 
 
This study has been approved by the Research Ethics Committee of the Faculty of Health Sciences of 
the University of Cape Town. It will be conducted according to the ethical guidelines and principles 
of the International Declaration of Helsinki, the South African Guidelines for Good Clinical Practice 
and the Medical Research Council (MRC) Ethical Guidelines for Research. 
 
This trial is being run by the Applied Cognitive Sciences and Experimental Neuropsychology Testing 
(ACSENT) laboratory and the Divisions of Neurology and Geriatric Medicine in the Department of 
Medicine at the University of Cape Town. I aim to recruit a total of 90 participants over a period of 18 
months. 
 
What is this research study all about?  
 
Some people develop memory problems as they get older. Many elderly people have mild memory 
difficulties.  However, in a few, the problem may be more severe. I am interested in finding out more 
about how the difficulties with memory and other higher brain functions change over time.  In order 
to do so, I should like to investigate the course of these changes using a small number of methods. 
These include questions you would need to answer about yourself and tests of memory and other 
higher brain functions.  
 
I am interested in testing people both with memory difficulties and those without, so that we can 
compare the two groups. In this way I might be able to better understand the progression of change in 
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brain function associated with memory impairment. My research findings may aid in the early 
detection and treatment of these conditions and help improve the design of drug intervention trials 
associated with these conditions in the future. 
 
Procedures 
 
If you agree to take part in the study you will be required to partake in a short telephonic interview 
about your medical history. This is done to ensure you meet all the conditions required to enter the 
study. You will then be invited to visit our clinic on three separate days over a two week period.  At 
these visits to our clinic I shall: 
 
(4) interview your relative/friend (someone who knows you well) to find out whether he/she 
thinks you have any memory difficulties. 
 
(5) ask you to complete a short questionnaire about your mental and emotional functioning. 
 
(6) perform tests of your memory and other higher mental functions. These will be conducted in 
a quiet, relaxed atmosphere. I expect that these tests will be about an hour’s duration. 
However, there will be opportunities to rest in-between tests. 
 
The questionnaires and the tests will be administered during the first visit, however for the subsequent 
two visits you will only be required to complete the tests. After the three baseline visits I would like to 
re-assess your memory and other higher functions again after six months and twelve months, 
respectively, provided you continue to consent to participation in the study. 
 
If I find that you or your relative/friend has a significant memory problem that is interfering with your 
daily living activities, we shall refer you to a Memory Clinic. Your permission will always be sought 
first. 
 
What will your responsibilities be? 
 
You will be required to attend the study visit at the appropriate time and to participate as fully as you 
can with the tests and questionnaires. You should answer the questions as fully and honestly as you 
can. If there are any questions that you cannot, or do not wish to answer, you should tell us so. 
 
Will you benefit from taking part in this study? 
 
You will receive little direct benefit from the study. However, you will undergo a range of cognitive 
tests. As previously indicated, we shall, with your permission, refer you to the appropriate medical 
services if any treatable abnormalities are found. 
Are there any risks in your taking part in this research? 
 
You may feel uncomfortable about answering some of the questions about yourself or your 
friend/relative. Some people don’t like talking, or knowing about, problems related to memory or 
thinking. You should feel free to mention your feelings or concerns to any member of the study team. 
 
If you do not agree to take part, what alternatives do you have? 
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You are free not to participate in the study or to refuse parts of the study.  
 
Who will have access to your medical records? 
The information collected about you will be treated as confidential and protected.  If it is used in a 
publication or thesis, your identity will remain anonymous.  Only the direct study team will have full 
access to the information. If we need to refer you to a clinic for treatment, we will provide them with 
the relevant information needed to treat your condition.  
 
Will you be paid to take part in this study and are there any costs involved? 
 
You will not be paid to take part in the study but your transport costs will be covered for the study 
visit. You will be reimbursed for the sum of R50-00 at each visit to the research site. There will be no 
costs involved for you, if you do take part. 
 
Is there anything else that you should know or do? 
 You should inform your family practitioner or usual doctor that you are taking part in a 
research study.   
 You can contact me on 079 334 4404 if you have any further queries or encounter any 
problems. 
 You can contact the Research Ethics Committee of the Health Sciences Faculty of the 
University of Cape Town 021-4066338 if you have any concerns or complaints that have not 
been adequately addressed by your study doctor. 
 You will receive a copy of this information and consent form for your own records. 
 
Declaration by participant and/or friend/relative/guardian 
 
By signing below, I …………………………………..…………., hereby agree to take part in the 
research study entitled: “Intraindividual Variability in the Progression of Alzheimer’s disease: A 
longitudinal trajectory of cognitive decline” 
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately 
answered. 
 I understand that taking part in this study is voluntary and I have not been pressurised to 
take part. 
 I may choose to leave the study at any time and will not be penalised or prejudiced in any 
way. 
 I may be asked to leave the study before it has finished, if the study doctor or researcher 
feels it is in my best interests, or if I do not follow the study plan, as agreed to. 
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Signed at (place) ......................…........…………….. on (date) …………....…….2017 
 
 
.........................................................................   ......................................................................  
Signature of participant Signature of witness 
 
 
.........................................................................   ......................................................................  
Signature of relative/friend/guardian Signature of witness 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as discussed 
above 
 
Signed at (place) ......................…........…………….. on (date) …………....….. 2017 
 
 
.........................................................................   ......................................................................  
Signature of investigator Signature of witness 
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Appendix G  
MRI Checklist 
 
 
 
 
  MRI Volunteer Screening Form 
                      
Volunteer Information:   
                         
Name  Contact number 
Date of Birth Project name 
Weight Principle investigator 
 
The following information is very important to ensure your safety and to prevent any interference 
during the MR procedure. 
 
Please answer the following questions (mark with an X):                   Yes No Don’t 
Know 
Pacemaker    
Aneurism clips    
Artificial heart valve    
Vena cava filter    
Prosthesis (e.g. eye, breast etc)    
Shrapnel in eye or body    
Neurostimulator    
Cochlear implant (ear) or hearing aid    
? Diabetic    
? Renal impairment    
129 
 
? Asthma    
? Allergies    
? Any other implants (e.g. screws, plates, joint replacements)    
? Pregnant    
? Previous MRI investigation with intravenous contrast    
Is there any other device implanted or are there 
any other ailments that you think that we should be 
aware of? 
   
                                                                                                                      
I hereby acknowledge that the potential risks of the examination have been explained to me and that 
during the course of the investigation it may be necessary for the intravenous injection of a contrast 
agent. 
 
Attention: It is the policy of this institution not to discuss results of the MR investigation with the 
patients for ethical reasons.  All enquiries in this regard should be directed to the referring physician. 
 
 
Signature:                                                                     Date: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cape Universities Brain Imaging Centre 
Fisan Building, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, 7505 
Tel:  27-21-938-9646   Fax: 27-21-938-9728   www.sun.ac.za/cubic 
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Appendix H 
MRI Consent Form 
 
TITLE OF THE RESEARCH PROJECT: Intraindividual Variability in the Progression of 
Alzheimer’s disease: A longitudinal trajectory of cognitive decline 
 
PROTOCOL NUMBER: 167/2014 
 
PRINCIPAL INVESTIGATOR: Mr. Bjorn U. Christ 
SECONDARY INVESTIGATOR: Ms. Kara Engelbrecht  
 
ADDRESS:   Department of Psychology, PD Hahn Psychology Building, University 
Avenue, University of Cape Town, Rondebosch, Cape Town, 7701 
 
CONTACT NUMBER: +27 72 0710 346 
 
I am inviting you to receive a magnetic resonance imaging scan (MRI) as part of a research 
project. Please take some time to read the information presented here. It explains the details 
of the MRI scanning procedure. PLEASE NOTE: For specific details of the project please 
refer to your INFORMATION LEAFLET. This consent form will only describe the details 
of the MRI scan.  
 
If there are any aspects of the project you do not understand, please do not hesitate to ask the 
study staff or doctor.  It is important that you are fully satisfied that you clearly understand 
what this research entails and how you could be involved.  Your participation in the study is 
entirely voluntary and you are free to decline to participate.  If you say no, this will not affect 
you negatively in any way whatsoever.  It will not affect any future medical treatment you 
may need. You are also free to withdraw from the study at any point, even if you did initially 
agree to take part. You do not have to give a reason for withdrawing. 
 
This study has been approved by the Research Ethics Committee of the Faculty of Health 
Sciences of the University of Cape Town. It will be conducted according to the ethical 
guidelines and principles of the International Declaration of Helsinki, the South African 
Guidelines for Good Clinical Practice and the Medical Research Council (MRC) Ethical 
Guidelines for Research. 
 
This trial is being run by the Applied Cognitive Sciences and Experimental Neuropsychology 
Testing (ACSENT) laboratory and the Divisions of Neurology and Geriatric Medicine in the 
Department of Medicine at the University of Cape Town. I aim to recruit a total of 90 
participants over a period of 18 months. 
 
What is a magnetic resonance imaging (MRI) scan?  
 
Magnetic resonance imaging is a procedure used to scan the body without X-rays. The MRI 
device utilizes a very strong magnet. This magnet sends out powerful magnetic fields during 
the examination. The magnetic fields allow us to pick up signals arising from the brain which 
are then measured and captured by a computer. The computer then turns the signals from the 
brain into pictures of the brain. The scan is completely painless and, to our knowledge, 
damaging long-term effects from the procedure have not been detected. 
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What does the scan involve? 
 
The MRI machine consists of an enclosed tube or tunnel with a narrow bed placed inside, 
where you will lie for the duration of the scan. The scan will take approximately 40 minutes. 
During the scan, while you lie on the narrow bed, you will hear loud thudding noises. It is 
very important that you lie completely still because even slight movements will blur the 
image. 
 
Procedures 
 
If you agree to undergo an MRI you will be required to complete a short MRI safety 
questionnaire. This is done to assess your risk prior to the scan and to ensure your safety 
during the MRI procedure. Once you have completed the questionnaire the MRI technician 
will explain the full MRI procedure to you in preparation for your scan.  
 
You will not be required to perform any additional tasks while you are in the MRI scanner. 
 
Are there any risks in your taking part in this research? 
 
The MRI scanning procedure requires that you be confined in a small partially enclosed 
space. Some individuals find this to be uncomfortable and may become nervous. During the 
scan you may also hear loud thudding noises. We will however attempt to reduce the noise 
through our noise reduction facilities. 
 
In addition, the magnetism of the machine attracts certain metals; therefore, people with these 
metals within their bodies (such as pacemakers, infusion pumps, aneurysm clips, metal 
prostheses, joints, rods, or plates) will be excluded from the scanning component of the study. 
The “metal” in dental fillings is less responsive to magnetism and is therefore allowed.  
 
The MRI technician will ask you if you have any metals within your body. You will be 
expected to notify the investigator conducting the study of any metal in your body, other 
than dental fillings. There are no other known side effects resulting from exposure to the 
MRI scan. 
 
Because this is a research procedure, there may be risks that are currently unforeseeable. In 
the studies performed so far, there have been no significant risks reported in animals or 
humans for similar exposures. 
 
If you do not agree to take part, what alternatives do you have? 
 
You are free not to participate in the study or to refuse parts of the study.  
 
Who will have access to your medical records? 
 
The information collected about you – which includes your Groote Schuur Hospital medical 
history (e.g. the records of the Geriatric Unit and the Memory Clinic), cognitive test 
performance, and MRI data – will be treated as confidential and protected.  If it is used in a 
publication or thesis, your identity will remain anonymous.  Only the direct study team will 
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have full access to the information. If we need to refer you to a clinic for treatment, we will 
provide them with the relevant information needed to treat your condition. 
Will you be paid to take part in this study and are there any costs involved? 
You will not be paid to take part in the study but your transport costs will be covered for the 
study visit. You will be reimbursed for the sum of R200-00 at each visit to the research site. 
There will be no costs involved for you, if you do take part. 
Is there anything else that you should know or do? 
 You should inform your family practitioner or usual doctor that you are taking part in
a research study.
 You can contact me on +27 72 0710 346 if you have any further queries or encounter
any problems.
 You can contact the Research Ethics Committee of the Health Sciences Faculty of the
University of Cape Town 021-4066338 if you have any concerns or complaints that
have not been adequately addressed by your study doctor.
 You will receive a copy of this information and consent form for your own records.
PLEASE FIND THE DECLARATION ON THE FOLLOWING PAGE 
133 
Declaration by participant and/or friend/relative/guardian 
By signing below, I …………………………………..…………., hereby agree to take part in 
the research study entitled: “Intraindividual Variability in the Progression of Alzheimer’s 
disease: A longitudinal trajectory of cognitive decline” 
I declare that: 
 I have read or had read to me this information and consent form and it is written in a
language with which I am fluent and comfortable.
 I have had a chance to ask questions and all my questions have been adequately
answered.
 I understand that taking part in this study is voluntary and I have not been pressurised
to take part.
 I may choose to leave the study at any time and will not be penalised or prejudiced in
any way.
 I may be asked to leave the study before it has finished, if the study doctor or
researcher feels it is in my best interests, or if I do not follow the study plan, as agreed
to.
Signed at (place) ......................…........…………….. on (date) …………....…….2016 
………………………………………… …………………………………… 
Signature of participant Signature of witness 
………………………………………… …………………………………… 
Signature of relative/friend/guardian Signature of witness 
Declaration by investigator 
I (name) ……………………………………………..……… declare that: 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them.
 I am satisfied that he/she adequately understands all aspects of the research, as
discussed above
Signed at (place) ......................…........…………….. on (date) …………....….. 2016 
………………………………….. ……………………………….……. 
Signature of investigator Signature of witness 
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Appendix I 
Ethics Approval Forms 
signature removed to avoid exposure online
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Ethics Approval Update and Amendment 
signature removed  
137 
signature removed 
138 
Ethics Approval Update 
signature removed to avoid exposure online
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140 
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142 
143 
signature removed to avoid exposure online
